Curriculum Vitae
(last updated: July 2023)

Wei-Hsuan Jenny Lo-Ciganic, MSPharm, MS, PhD
Associate Professor
Department of Pharmaceutical Outcomes & Policy, College of Pharmacy
University of Florida

BIOGRAPHICAL INFORMATION

Business Address:	University of Florida, College of Pharmacy, P.O. Box 100496 1225 Center Drive Gainesville, Florida 32610	E-mail:	wlociganic@cop.ufl.edu
Business Phone:	(352) 273-6255	Fax:	(352) 273-6270

EDUCATION

Post-Graduate

2013-2014	University of Pittsburgh, Center for Pharmaceutical Policy and Prescribing (CP3)	Postdoctoral Associate in pharmaceutical health service research

Graduate

2006-2013	University of Pittsburgh, Graduate School of Public Health	PhD, Epidemiology

Major field: Pharmacoepidemiology
Dissertation: Pharmacoepidemiologic Studies: An Interrupted-Time Series Analysis on Drug Utilization and Evaluation of Beneficial or Adverse Drug Effects
Major advisor: Janice Zgibor, RPh, PhD

2011-2013	University of Pittsburgh, School of Medicine Advisor: Joseph T Hanlon, PharmD, PhD	Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and Training Program
2008-2010	University of Pittsburgh, Graduate School of Public Health	M.S., Biostatistics

Major field: machine learning (classification tree)
Thesis: Identifying and Validating Type 1 and Type 2 Diabetic Cases Using Administrative Data: A Tree-Structured Model
Major advisor: Roslyn Stone, PhD

| 2003-2005 | National Cheng Kung University (Tainan, Taiwan) | M.S., Clinical Pharmacy |

Major field: Clinical Pharmacy, nephrology
Thesis: Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Protection of Cardiovascular Disease and Residual Renal Function in Peritoneal Dialysis Patients
Major advisor: Prof. Yea-Huei Kao Yang, RPh

Undergraduate

| 1998-2003 | National Taiwan University (Taipei, Taiwan) | B.S., Pharmacy; Minor in Horticulture |

Internship/Fellowship

2003-2005	National Cheng Kung University Hospital, Tainan, Taiwan	Clinical Pharmacist Fellow
2002	Merck Sharp & Dohme (LA) Corp., Medical Department. Taipei, Taiwan	Intern
2002	Shin-Hsin-Ho Community Pharmacy, Taichung, Taiwan	Pharmacist intern

---

EMPLOYMENT

Academic Appointments

Years	Appointment	Institution, location
2021-Present	Associate Professor (tenured)	Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville, FL
2018-2021	Assistant Professor	Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville, FL
2015-2018	Adjunct Research Faculty	University of Arizona Arthritis Center, University of Arizona, Tucson, AZ
2015-2018	Core Research Investigator	Center for Population Science & Discovery, University of Arizona, Tucson, AZ
2015-2018	Assistant Professor	Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ
2015-2018	Assistant Professor (secondary appointment)	Department of Epidemiology and Biostatistics, College of Public Health, University of Arizona, Tucson, AZ
2011-2013	Data Manager	Center for Aging and Population Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA

| 2006-2011 | Graduate Student Researcher | Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA |
| 2004-2006 | Research Associate | Institute of Clinical Pharmacy, National Cheng-Kung University, Tainan, Taiwan |

HONORS AND AWARDS

2022	**2022 University of Florida College of Pharmacy Research Impact Award**
2021	**2021 Young Outstanding Alumni Award of National Cheng-Kung University, Taiwan**
2021	**2020 Outstanding Reviewer,** Annals of Internal Medicine
2020	**2020 University of Florida College of Pharmacy Outstanding Clinical Science Publication Award**
2020	**2020 University of Florida Excellence Awards for Assistant Professors**
2019	**2018 Best Reviewer,** Pharmacoepidemiology and Drug Safety
2019	**2018 Outstanding Reviewer,** Annals of Internal Medicine
2017	**Grant Mentoring and Career Development Program Awardee,** U.S. Bone and Joint Initiative/Bone and Joint Canada Young Investigators Initiative (YII)
2017	**2017 Best Podium Presentation Award,** 2017 International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual Meeting, Boston, MA, USA
2017	**2016 Outstanding Reviewer,** Annals of Internal Medicine
2016	**2015 Best Reviewer,** Pharmacoepidemiology and Drug Safety
2016	**2015 Outstanding Reviewer,** Annals of Internal Medicine
2015	**2015 Top 10 Addiction Article,** American Society of Addiction Medicine (ASAM) Article: Gordon AJ, **Lo-Ciganic W,** Cochran G, Gellad WF, Cathers T, Kelley D, Donohue JM. Patterns of Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program. J Addict Med 2015 9:470-7
2015	**2015 Poster Finalist Award,** 2015 ISPOR 20th Annual Meeting, Philadelphia, PA, USA
2013	**Honorable Mention for the Erikson Foundation Award,** American Public Health Association

Article: Zgibor JC, Schlenk EA, Vater LB, Kola S, Vander Bilt J, Woody SE, Jacob ME, **Lo-Ciganic W**, Brenckle A, Brandenstein J, Kwoh CK, Boudreau R, Albert SM, Conroy

MB, Newman AB. Partnership Building and Implementation of and Integrated Healthy-Aging Program. Prog Community Health Partnersh. 2016; 10(1):123-132.

2012   **Graduate Student Honoree,**
Graduate School of Public Health, University of Pittsburgh. 2012 Graduation convocation

2011   **Best Thesis Award in the Department of Biostatistics,**
Graduate School of Public Health, University of Pittsburgh. Honored by the Omicron Chapter of the Delta Omega National Honor Society of Public Health

Thesis: "Identifying and Validating Type 1 and Type 2 Diabetic Cases using Administrative Data: A Tree Structured Model"

2007   **Public Health Dean's Scholarship,** Graduate School of Public Health, University of Pittsburgh

2005   **Best Clinical Thesis Award**, Taiwan Society of Nephrology 2005 Annual Meeting, Taipei, Taiwan

Thesis: "Cardiovascular Disease and Residual Renal Function in Peritoneal Dialysis Patients: Protective Roles of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers"

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

2015-present	American Association of Colleges of Pharmacy (AACP)
2015-present	International Society of Pharmacoepidemiology (ISPE)
2015-2020	American College of Rheumatology (ACR)-Association of Rheumatology Health Professionals (ARHP)
2013-present	International Society of Pharmaceutical and Outcome Research (ISPOR)
2016-2018	Academy Health
2012-2013	Gerontology Society of America (GSA)
2005-2006, 2013	American College of Clinical Pharmacy (ACCP)

SERVICE AND OUTREACH

National and International

Years	Role	Committee	Organization
2021-2022	Co-Chair	Quality Metrics Expert Panel (QMEP)	Pharmacy Quality Alliance (PQA)

Years	Role	Committee	Organization
2020-2021	Member	Clinical Trials Network (CTN) Computer Intelligence (CI)/Artificial Intelligence (AI) Workgroup	National Institute on Drug Abuse (NIDA)
2018-present	Member	Quality Metrics Expert Panel (QMEP)	PQA
2017-2018	Co-Chair	Stakeholder Advisory Panel C Co-Chair: Measurements of "Inappropriate Duplicate Therapy", "Adult Immunization" and "Polypharmacy"	PQA
2017-2018	Member	PQA Measure Validity Panel (MVP)	PQA
2016-2017	Member	Opioid and Pain Management Expert Panel	National Committee for Quality Assurance (NCQA)
2016	Member	Measurement Development Team 10: "Treatment of Chronic Hepatitis C: Completion of Therapy"	PQA
2015	Member	Measurement Development Team 7: "Triple Threat: Concurrent Use of Opioids, Benzodiazepine or Nonbenzodiazepine Sedative/Hypnotics, and Muscle Relaxants"	PQA

National/International Study Section or External Grant Review Committee

Years	Role	Committee	Organization
03/22/2023	Chair	ZDA1 TXT-E (M2) HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards	NIDA, special review panel
10/31/2022	External Reviewer	Faculty Development Competitive Research Grants Program	Nazarbayev University
7/21/2022	Member	ZRG1 IFCN-M (50) Heal Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans	NIDA, special review panel
12/8/2021	Member	PAR-19-064: Mechanism for Time-Sensitive Drug Abuse Research	NIDA, special review panel
11/05/2021	Mail-in Reviewer	Small Business Innovation Research (SBIR) grants	National Science Foundation (NSF)
10/14/2021-10/15/2021	Member	Social Sciences and Population Studies B (SSPB) Study Section; Population Sciences and Epidemiology Integrated Review Group	National Institute of Health (NIH), Center for Scientific Review (CSR)

Date	Role	Description	Organization
5/4/2021	External Reviewer	Health Data for Action (Data Access Award)-Leveraging Health Data for Actionable Insights	Robert Wood Johnson Foundation
2/4/2021-2/5/2021	Member	Social Sciences and Population Studies A (SSPA) Study Section; Population Sciences and Epidemiology Integrated Review Group	NIH CSR
5/15/2020	External Reviewer	Health Research (opioid use)	PSI Foundation
11/14/2019	Member	ZRG1 PSE-W (55) R PAR Panel: Accelerating the Pace of Drug Abuse Research Using Existing Data	NIH CSR
11/4/2019	External Reviewer	Office of Women's Health (OWH) Intramural Research Program	US Food and Drug Administration (FDA)
2/14/2019-2/15/2019	Member	Social Sciences and Population Studies B (SSPB) Study Section; Population Sciences and Epidemiology Integrated Review Group	NIH CSR
11/19/2018-11/20/2018	Member	ZRG1 RPHB-Z 10 B Study Section, Small Business: Disease Prevention and Management, Risk Reduction and Health Behavior Change	NIH, CSR Special Emphasis Panel
2017	External Panel Reviewer	UNC Inter-institutional Planning Grant Program, Machine Learning Panel	American Association for the Advancement of Science (AAAS)

University Committees

Years	Role	Committee	Organization
2021-2023	Member	Artificial Intelligence Decision Support Search Committee	University of Florida, Health Sciences Center
2022	Grant Reviewer	Precision Health Initiative Pilot Project Award Application	University of Florida Clinical and Translational Science Institute
2021-present	Member	Quality Enhancement Plan (QEP) Committee for the accreditation with the Southern Association of Colleges and Schools Commission on Colleges	University of Florida
2020-present	Member	Artificial Intelligence Academic Taskforce Committee	University of Florida

| 2017 | Grant Reviewer | Faculty Seed Grant | University of Arizona |

College Committees

Years	Role	Committee	Organization
2020-present	Co-Chair	Artificial Intelligence Committee	University of Florida, College of Pharmacy
2020-present	Member	Center for Drug Evaluation and Safety (CoDES)	University of Florida
2019-present	Member	Center for Addiction Research & Education (CARE)	University of Florida
2019-present	Member	International Committee	University of Florida, College of Pharmacy
2016-2018	Member	Research Affairs Committee	University of Arizona, College of Pharmacy

Departmental Committees

Years	Role	Committee	Organization
2023 – present	Chair	Department of Pharmaceutical Outcomes and Policy, Faculty Search Committee	University of Florida, College of Pharmacy
2017-2018	Member	Department of Pharmacy, Practice and Science Peer Review Committee	University of Arizona, College of Pharmacy
2015-2016	Member	Department of Pharmacy, Practice and Science Mission, Vision, and Planning (MVP) Committee	University of Arizona, College of Pharmacy

Conferences Review Committees

Years	Role	Committee	Organization
2020	Program committee member	International Workshop on Data-driven Analysis and Decisions for the Opioid Epidemic (under the 8th IEEE International Conference on Healthcare Informatics)	Institute of Electrical and Electronics Engineers
2019	Reviewer	Abstract reviewer for the annual mid-year conference	International Society of Pharmacoepidemi

			olology (ISPE)
2019 (February)	Judge	Poster presentation (addition) judge for the annual research showcase	University of Florida, College of Pharmacy
2018	Reviewer	Abstract reviewer for the annual conference	American College of Rheumatology (ACR)-Association of Rheumatology Health Professionals (ARHP)
2018	Judge	Podium presentation (cardiovascular disease) judge for the annual conference	International Society of Pharmacoeconomics and Outcomes Research (ISPOR)
2017	Judge	Podium presentations (Diabetes section) judge for the annual conference	ISPOR
2016	Judge	Podium presentations (cardiovascular disease/adherence) judge for the annual conference	ISPOR
2015	Reviewer	Abstract Review Committee for the Annual conference, epidemiology and methodology section	ISPOR

Ad-hoc Reviewer for the following journals, by alphabetical order (total articles reviewed to date):

Time	Journal name (by alphabetical order)	Total articles reviewed to date
2018-present	Addiction	4
2018-present	American Journal of Cardiovascular Drug	1
2021-present	American Journal of Epidemiology	1
2015-present	Annals of Internal Medicine	10
2020-present	BMC Musculoskeletal disorders	1
2016-present	CNS Drug	1
2017-present	JAMA Internal Medicine	2
2020-present	Journal of Addiction Medicine	1
2016-present	Journal of General Internal Medicine	2
2011-present	Journal Diabetes Science Technology	1
2021-present	Lancet Digital	2
2016-present	Medical Care	1
2019-present	Osteoarthritis and Cartilage	1
2019-present	Pain Medicine	2
2015-present	Pharmacoepidemiology and Drug Safety	6
2020-present	PLoS One	1
2018-present	Research in Social and Administrative Pharmacy	1
2018-present	Transaction on Management Information System	1

PUBLICATIONS

NCBI bibliography: https://www.ncbi.nlm.nih.gov/myncbi/1b17ChgSptvk7/bibliography/public/
Google Scholar: https://scholar.google.com/citations?user=rHTPVzMAAAAJ&hl=en&oi=ao

Keys to indicate author relationship: self=bold; senior/corresponding author =underline; fellow =f; graduate student/student =g; post-doctoral associate/fellow =p; resident =r;

Refereed Journal Articles, Published

(statistics regarding impact factor and cited by others was updated on July 2023)

1. Keshwani S, Smith SM, Brown J, **Lo-Ciganic W**, Yang S$_{(g)}$, Smolinski NE, Hincapie-Castillo JM. Trends in Prescribing of Non-Steroidal Anti-Inflammatory Medications in the US Ambulatory Care Setting from 2006-2016. J Pain. 2023 Jun 15:S1526-5900(23)00442-X. DOI: 10.1016/j.jpain.2023.06.008. Epub ahead of print. PMID: 37330160. **(Impact factor: 5.38; Cited by N/A; Altmetric score: N/A)**.

2. McDaniel CC, **Lo-Ciganic W**, Garza KB, Kavookjian J, Fox BI, Chou C. Medication use and contextual factors associated with meeting guideline-based glycemic levels in diabetes among a nationally representative sample. Front Med (Lausanne). 2023 May 31;10:1158454. DOI: 10.3389/fmed.2023.1158454. PMID: 37324129; PMCID: PMC10264805. **(Impact factor: 5.06; Cited by N/A; Altmetric score: N/A)**.

3. Jiang X$_{(g)}$, Song HJ$_{(p)}$, Chang CY$_{(g)}$, Wilson DL, **Lo-Ciganic W**, Park H. Impact of direct-acting antivirals on hepatocellular carcinoma and mortality among Medicaid beneficiaries with hepatitis C. Med Care. 2023 May 23. DOI: 10.1097/MLR.0000000000001870. Epub ahead of print. PMID: 37223993. **(Impact factor: 3.18; Cited by N/A; Altmetric score: 2)**.

4. Kang HR$_{(p)}$, Jones BL, **Lo-Ciganic W**, DeRemer CE, Dietrich EA, Huang PL, Park H. Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding. Res Pract Thromb Haemost. 2023 Mar 27;7(3):100131. DOI: 10.1016/j.rpth.2023.100131. PMID: 37159747; PMCID: PMC10163671. **(Impact factor: 5.95; Cited by N/A; Altmetric score: N/A)**.

5. Park H, Jones BL, Huang PL, Kang HR$_{(p)}$, Dietrich EA, DeRemer CE, **Lo-Ciganic W**. Trajectories of oral anticoagulation adherence and associated clinical outcomes during long-term anticoagulation among Medicare beneficiaries with venous thromboembolism. Ann Pharmacother. 2023 Mar 31:10600280231155489. DOI: 10.1177/10600280231155489. Epub ahead of print. PMID: 36999519. **(Impact factor: 3.15; Cited by N/A; Altmetric score: N/A)**.

6. Chang CY$_{(g)}$, Park H, Hincapie-Castillo JM, Heldermon CD, Diaby V, Yang S$_{(g)}$, Wilson DL, **Lo-Ciganic W**. Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression. J Manag Care Spec Pharm. 2023 Apr;29(4):431-445. DOI: 10.18553/jmcp.2023.29.4.431. PMID: 36989452. **(Impact factor: 3.02; Cited by N/A; Altmetric score: 1)**.

7. Wang Y$_{(g)}$, Wilson DL, Fernandes D, Adkins LE, Bantad A, Copacia C, Dharma N, Huang PL, Joseph A, Park TW, Budd J, Meenrajan S, Orlando FA, Pennington J, Schmidt S, Shorr R, Uphold CR, **Lo-Ciganic W**. Deprescribing strategies for opioids and benzodiazepines with emphasis on concurrent use: a scoping review. J Clin Med. 2023 Feb 23;12(5):1788. DOI: 10.3390/jcm12051788. PMID: 36902574; PMCID: PMC10002935. **(Impact factor: 4.96; Cited by N/A; Altmetric score: 2)**.

8. Kang HR(p), Dietrich EA, Huang PL, **Lo-Ciganic W**, DeRemer CE, Park H. Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism. Clin Transl Sci. 2023 Jun;16(6):946-954. DOI: 10.1111/cts.13510. Epub 2023 Mar 23. PMID: 36891985; PMCID: PMC10264957. **(Impact factor: 4.52; Cited by N/A; Altmetric score: 2)**.

9. Jiang X(g), Song HJ(p), Chang CY(g), Wilson D, Guo J, **Lo-Ciganic W**, <u>Park H</u>. Disparities in access to hepatitis C treatment among Arizona Medicaid beneficiaries with chronic hepatitis C. Med Care. 2023 Feb 1; 61(2):81-86. DOI: 10.1097/MLR.0000000000001801. Epub 2022 Dec 1. PMID: 36453625; PMCID: PMC9839474. **(Impact factor: 3.18; Cited by N/A; Altmetric score: 3)**.

10. Park H, **Lo-Ciganic W**, Huang J, Wu Y, Henry L, Peter J, Sulkowski M, Nelson DR. Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection. Sci Rep. 2022;12(1):18094. DOI: 10.1038/s41598-022-22819-4. PMID: 36302828; PMCID: PMC9613877. **(Impact factor: 4.01; Cited by N/A; Altmetric score: 2)**.

11. Jiang X(g), Diaby V, Vouri SM, **Lo-Ciganic W**, Parker RL, Wang W, Chang SH, Wilson DL, Henry L, <u>Park H</u>. Economic impact of universal hepatitis C virus testing for middle-aged adults who inject drugs. Am J Prev Med. 2023 Jan;64(1):96-104. DOI: 10.1016/j.amepre.2022.08.016. Epub 2022 Oct 17. PMID: 36257884; PMCID: PMC10074824. **(Impact factor: 6.60; Cited by N/A; Altmetric score: 3)**.

12. Park H, Kang HR(p), Huang PL, **Lo-Ciganic W**, DeRemer CE, Wilson D, <u>Dietrich EA</u>. Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism. Clin Transl Sci. 2023 Jan;16(1):128-139. DOI: 10.1111/cts.13433. Epub 2022 Oct 17. PMID: 36200137; PMCID: PMC9841301. **(Impact factor: 4.52; Cited by N/A; Altmetric score: 1)**.

13. Huang S(g), Lewis MO(g), Bao Y, Adekkanattu P, Adkins LE, Banerjee S, Bian J, Gellad WF, Goodin AJ, Luo Y, Fairless JA, Walunas TL, Wilson DL, Wu Y, Yin P, Oslin DW, Pathak J, **<u>Lo-Ciganic W</u>**. Predictive modeling for suicide-related outcomes and risk factors among patients with pain conditions: a systematic review. J Clin Med. 2022 Aug 17;11(16):4813. DOI: 10.3390/jcm11164813. PMID: 36013053; PMCID: PMC9409905. **(Impact factor: 4.96; Cited by N/A; Altmetric score: 5)**.

14. Keshwani S, Maguire M, Goodin A, **Lo-Ciganic W**, Wilson DL, Hincapie-Castillo JM. Buprenorphine use trends following removal of prior authorization policies for the treatment of opioid use disorder in 2 state Medicaid programs. JAMA Health Forum. 2022 Jun 24;3(6):e221757. DOI: 10.1001/jamahealthforum.2022.1757. PMID: 35977240; PMCID: PMC9233239. (**Impact factor: N/A ; Cited by 3; Altmetric score: 16**).

15. Yang S(g), Hincapie-Castillo JM, Ke X, Schelfhout J, Ding H, Sher MR, Zhou L, Chang CY, Wilson DL, **<u>Lo-Ciganic W</u>**. Evaluation of cough medication use patterns in ambulatory care settings in the United States: 2003-2018. J Clin Med. 2022 Jun 25;11(13):3671. DOI: 10.3390/jcm11133671. PMID: 35806956; PMCID: PMC9267927. (**Impact factor: 4.96; Cited by 2; Altmetric score: N/A**).

16. Huang S(g), Yang S(g), Ly S, Yoo RH, **Lo-Ciganic W**, Eadon MT, Schleyer T, Whipple E, <u>Nguyen KA</u>. Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms: a systematic review. Eur J Clin Pharmacol. 2022 Aug;78(8):1217-1225. DOI: 10.1007/s00228-022-03346-7. PMID: 35657416; PMCID: PMC9283278. (**Impact factor: 3.06; Cited by 1; Altmetric score: 7**).

17. **__Lo-Ciganic W__**, Donohue JM, Yang Q, Huang JL, Chang C-Y(g), Weiss JC, Guo J, Zhang HH, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Wilson DL, Kuza CC, Gellad WF. Developing and validating a machine-learning algorithm to predict opioid overdose among Medicaid beneficiaries in two US states: a prognostic modeling study. Lancet Digit Health. 2022 Jun;4(6):e455-e465. DOI: 10.1016/S2589-7500(22)00062-0. PMID: 35623798; PMCID: PMC9236281. **(Impact factor: 38.93; Cited by 7; Altmetric score: 58)**.

18. Chen C(g), Tighe PJ, **Lo-Ciganic W**, Winterstein AG, Wei YJ. Perioperative use of gabapentinoids and risk for postoperative long-term opioid use in older adults undergoing total knee or hip arthroplasty. J Arthroplasty. 2022 Nov;37(11):2149-2157.e3. DOI: 10.1016/j.arth.2022.05.018. Epub 2022 May 13. PMID: 35577053; PMCID: PMC9588599. (**Impact factor: 4.44; Cited by N/A; Altmetric score: 4**).

19. Hayes CJ, Cucciare MA, Martin BC, Hudson TJ, Bush K, **Lo-Ciganic W**, Yu H, Charron E, Gordon AJ. Using data science to improve outcomes for persons with opioid use disorder. Subst Abus. 2022;43(1):956-963. DOI: 10.1080/08897077.2022.2060446. PMID: 35420927. **(Impact factor: 2.34; Cited by 1; Altmetric score: 5)**.

20. Kang HR(p), **Lo-Ciganic W**, DeRemer CE, Dietrich EA, Huang PL, Park H. Effectiveness and safety of extended oral anticoagulant therapy in patients with venous thromboembolism: a retrospective cohort study. Clin Pharmacol Ther. 2022 Jul;112(1):133-145. DOI: 10.1002/cpt.2611. PMID: 35420702. **(Impact factor: 7.05; Cited by 2; Altmetric score: 8)**.

21. Guo J, Gellad WF, Yang Q, Weiss JC, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Kuza CC, Wilson DL, **Lo-Ciganic W**. Changes in predicted opioid overdose risk over time in a state Medicaid program: a group-based trajectory modeling analysis. Addiction. 2022 Aug;117(8):2254-2263. DOI: 10.1111/add.15878. PMID: 35315173. **(Impact factor: 7.26; Cited by N/A; Altmetric score: 50)**.

22. Yang S(g), Orlova Y, Lipe A, Boren M, Hincapie-Castillo JM, Park H, Chang C-Y(g), Wilson DL, Adkins L, **__Lo-Ciganic W__**. Trends in the management of headache disorders in US emergency departments: analysis of 2007–2018 National Hospital Ambulatory Medical Care Survey Data. J Clin Med. 2022 Mar 3;11(5):1401. DOI: 10.3390/jcm11051401. PMID: 35268492; PMCID: PMC8910868. (**Impact factor: 4.96; Cited by 4; Altmetric score: 35**).

23. Chen C(g), Winterstein AG, **Lo-Ciganic W**, Tighe PJ, Wei YJ. Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: A population-based cohort study. PLoS Med. 2022 Mar 1;19(3):e1003921. DOI: 10.1371/journal.pmed.1003921. PMID: 35231025; PMCID: PMC8887769. (**Impact factor: 11.61; Cited by 3; Altmetric score: 18**).

24. **__Lo-Ciganic W__**, Hincapie-Castillo J, Wang T(p), Ge Y, Jones BL, Huang JL, Chang CY(g), Wilson DL, Lee JK, Reisfield GM, Kwoh CK, Delcher C, Nguyen KA, Zhou L, Shorr RI, Guo J, Marcum ZA, Harle CA, Park H, Winterstein A, Yang S(g), Huang PL, Adkins L, Gellad WF. Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: Group-based multi-trajectory models. Addiction. 2022 Jul;117(7):1982-1997. DOI: 10.1111/add.15857. PMID: 35224799. (**Impact factor: 7.26; Cited by 4; Altmetric score: 11**).

25. DeRemer CE, Dietrich EA, Kang HR(p), Huang PL, **Lo-Ciganic W**, Park H. Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism. J Intern Med. 2022 Jun;

291(6):877-885. DOI: 10.1111/joim.13462. Epub 2022 Feb 22. PMID: 35192737. (**Impact factor: 13.07; Cited by 4; Altmetric score: 4**).

26.   Park H*, **Lo-Ciganic W***, Huang JL, Wu Y, Henry L, Peter J, Sulkowski M, Nelson DR. Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis. Hepatology. 2022;76(2):483-491. DOI: 10.1002/hep.32347. PMID: 35034373. (**Impact factor: 17.30; Cited by 7; Altmetric score: 22**).
      Co-first authors

27.   Unigwe I(g), Yang S(g), Song HJ(p), **Lo-Ciganic W**, Hincapie-Castillo JM, Cook R, Park H. Trends in sexually transmitted infections in United States ambulatory care clinics from 2005–2016. J Clin Med. 2021 Dec 24;11(1):71. DOI: 10.3390/jcm11010071. PMID: 35011812; PMCID: PMC8745575. (**Impact factor: 4.96; Cited by 1; Altmetric score: 1**).

28.   Chen C(g), **Lo-Ciganic W**, Winterstein AG, Tighe P, Wei YJ. Concurrent use of prescription opioids and gabapentinoids in older adults. Am J Prev Med. 2022 Apr;62(4):519-528. DOI: 10.1016/j.amepre.2021.08.024. Epub 2021 Nov 19. PMID: 34802816; PMCID: PMC9426287. **(Impact factor: 6.60; Cited by 1; Altmetric score: 3)**.

29.   Jiang X(g), Vouri SM, Diaby V, **Lo-Ciganic W**, Parker R, Park H. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C. J Manag Care Spec Pharm. 2021 Oct;27(10):1388-1402. DOI: 10.18553/jmcp.2021.27.10.1388. PMID: 34595949; PMCID: PMC8968723. **(Impact factor: 3.02; Cited by 3; Altmetric score: N/A)**.

30.   Marcum ZA, Chang C-Y(g), Barthold D, Holmes HM, **Lo-Ciganic W**. Industry payments to physicians and prescribing of branded memantine and donepezil combination. Neurol Clin Pract. 2021 Jun;11(3):181-187. DOI: 10.1212/CPJ.0000000000000870. PMID: 34484885; PMCID: PMC8382368. (**Impact factor: 1.24; Cited by 1; Altmetric score: 14)**.

31.   Jiang X(g), Parker R, Vouri SM, **Lo-Ciganic W**, Diaby V, Henry L, Park H. Cascade of hepatitis C virus care among patients with substance use disorders. Am J Prev Med. 2021 Oct;61(4):576-584. DOI: 10.1016/j.amepre.2021.04.013. Epub 2021 Jun 29. PMID: 34210584; PMCID: PMC8455419. **(Impact factor: 6.60; Cited by 2; Altmetric score: 4)**.

32.   Oueini R(g), Goodin A, Vouri SM, **Lo-Ciganic W**, Park H, Hincapie-Castillo JM. Changes in Schedule II oral opioid volume dispensed in a private payer following Florida's acute pain opioid restriction law. J Manag Care Spec Pharm. 2021;27:779-784. DOI: 10.18553/jmcp.2021.27.6.779. PMID: 34057389. **(Impact factor: 3.02; Cited by 7; Altmetric score: 4)**.

33.   Chinthammit C(g), Bhattacharjee S, **Lo-Ciganic W,** Axon DR(g), Slack M, Slack M, Bentley JP, Warholak TL. Association of low-income subsidy, Medicaid dual eligibility, and disability status with high-risk medication use among Medicare Part D beneficiaries. Res Social Adm Pharm. 2021 May 11:S1551-7411(21)00171-6. DOI: 10.1016/j.sapharm.2021.05.005. PMID: 34006485. (**Impact factor: 3.35; Cited by 2; Altmetric score: 4**).

34.   Tong J, Chen Z, Duan R, **Lo-Ciganic W**, Lyu T, Tao C, Merkel PA, Kranzler HR, Bian J, Chen Y. Identifying clinical risk factors for opioid use disorder using a distributed algorithm to combine real-world data from a large clinical data research network. AMIA Annu Symp Proc.

2021 Jan 25;2020:1220-1229. PMID: 33936498; PMCID: PMC8075517. **(Impact factor: 2.10; Cited by 4; Altmetric score: N/A)**.

35. **Lo-Ciganic W**, Donohue JM, Hulsey EG, Barnes S, Li Y, Kuza CC, Yang Q, Buchanich J, Huang JL, Mair C, Wilson DL, Gellad WF. Integrating human services and criminal justice data with claims data to predict risk of opioid overdose among Medicaid beneficiaries: a machine-learning approach. PLOS One. 2021;16(3): e0248360. DOI: 10.1371/journal.pone.0248360. PMID: 33735222. PMCID: PMC7971495. **(Impact factor: 3.75; Cited by 6; Altmetric score: 20)**.

36. Park H, Jiang X$_{(g)}$, Song HJ$_{(p)}$, Lo Re V 3rd, Childs-Kean LM, **Lo-Ciganic W**, Cook RL, <u>Nelson DR</u>. The Impact of direct-acting antiviral therapy on end stage liver disease among individuals with chronic hepatitis C and substance use disorders. Hepatology. 2021;74:566-581. DOI: 10.1002/hep.31732. PMID: 33544904. PMCID: PMC8339171. **(Impact factor: 17.30; Cited by 7; Altmetric score: 4)**.

37. Zhou L$_{(g)}$, Bhattacharjee S, Kwoh K, Tighe PJ, Reisfield GM, Malone DC, Slack M, Wilson DL, **Lo-Ciganic W**. Association between dual-trajectories of opioid and gabapentinoid use and healthcare expenditures among United States Medicare beneficiaries. Value Health. 2021; 24:196-205. DOI: 10.1016/j.jval.2020.12.001. PMID: 33518026. (**Impact factor: 5.16**; **Cited by 4; Altmetric score: N/A)**.

38. Guo J$_{(p)}$, **Lo-Ciganic W**, Yang Q, Huang JL, Weiss JC, Cochran G, Malone DC, Kuza CC, Gordon AJ, Donohue JM, Gellad WF. Predicting mortality risk after a hospital or emergency department visit for nonfatal opioid overdose. J Gen Intern Med. 2021; 36(4):908-915. DOI: 10.1007/s11606-020-06405-w. PMID: 33481168. (**Impact factor: 6.47**; **Cited by 2; Altmetric score: 11)**.

39. <u>Bhattacharjee S</u>, Lee JK, Vadiei N, Patanwala AE, Malone DC, Knapp SM, **Lo-Ciganic W**, Burke WJ. Health outcomes associated with adherence to antidepressant use during acute and continuation phases of depression treatment among older adults with dementia and major depressive disorder. J Clin Med. 2020;9(10):3358. DOI: 10.3390/jcm9103358. PMID: 33092169; PMCID: PMC7589937. (**Impact factor: 4.96; Cited by 6; Altmetric score: N/A**).

40. Xie J$_{(g)}$, Zhang B, Jian M, Zeng D, **Lo-Ciganic W.** Readmission prediction for patients with heterogeneous hazard: A trajectory-based deep learning approach. ACM Trans Manag Inf Syst 2021 June; 13(2): Article No: 14, pp1-27. DOI: 10.1145/3468780. (**Impact factor: 6.03; Cited by 5; Altmetric score: N/A**).

41. Chinthammit C$_{(g)}$, Bhattacharjee S, Slack M, Axon DR$_{(g)}$, Slack M, Bentley JP, Warholak TL, Wilson DL, **Lo-Ciganic W**. Geographic variation in the prevalence of high-risk medication use among Medicare Part D beneficiaries by hospital referral region. J Manag Care Spec Pharm. 2020; 26(10):1309-1316. DOI: 10.18553/jmcp.2020.26.10.1309. PMID: 32996396. (**Impact factor: 3.02; Cited by 1; Altmetric score: N/A**).

42. Tan T$_{(r)}$, Armstrong DG, Concha-Moore KC, Marrero DG, Zhou W, Calhoun E, Chang C-Y$_{(g)}$, **Lo-Ciganic W**. Association between race/ethnicity and the risk of amputation of lower extremities among Medicare beneficiaries with diabetic foot ulcers and diabetic foot infections.

BMJ Open Diabetes Res & Care 2020; 8,1: e001328. DOI: 10.1136/bmjdrc-2020-001328. PMID: 32843499. PMCID: PMC7449291. (**Impact factor: 4.19; Cited by 28; Altmetric score: 41**).

43. Song HJ(p), Squires P(g), Wilson D, **Lo-Ciganic WH**, Cook RL, Park H. Trends in HIV pre-exposure prophylaxis (PrEP) utilization and provider type patterns in the United States, 2012-2018. JAMA. 2020; 324: 395-397. PMID: 32720996. PMCID: PMC7589937. DOI: 10.1001/jama.2020.7312. (**Impact factor: 157.38; Cited by 15; Altmetric score: 6**).

44. Brown JD, **Lo-Ciganic W**, Shao H, Pahor M, Manini TM. Trajectories of short physical performance battery are strongly associated with future major mobility disability: results from the LIFE Study. J Clin Med. 2020; 9:2332. DOI: 10.3390/jcm9082332. PMID: 32707877. PMCID: PMC7465072. (**Impact factor: 4.96; Cited by 9; Altmetric score: N/A**).

45. **Lo-Ciganic W**, Huang JL, Zhang H, Weiss J, Kwoh CK, Donohue J, Gordon A, Gerald C, Malone D, Kuza C, Gellad WF. Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries: a prognostic study. PLoS One. 2020;15(7): e0235981. DOI: 10.1371/journal.pone.0235981. PMID: 32678860. PMCID: PMC7367453. (**Impact factor: 3.75; Cited by 21; Altmetric score: 14**).

46. Zhou L(g), Bhattacharjee S, Kwoh K, Tighe PJ, Reisfield GM, Malone DC, Slack M, Wilson DL, Chang C-Y(g), **Lo-Ciganic W**. Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: A retrospective cohort study. Addiction. 2020; 116(4):819-830. DOI: 10.1111/add.15189. PMID: 32648951. (**Impact factor: 7.26; Cited by 21; Altmetric score: 9**).

47. Bhattacharjee S, Lee JK, Vadiei N, Patanwala AE, Malone DC, Knapp SM, **Lo-Ciganic W**, Burke WJ. Extent and factors associated with adherence to Antidepressant treatment during acute and continuation phase depression treatment among older adults with dementia and major depressive disorder. Neuropsychiatr Dis Treat. 2020;16:1433-1450. DOI: 10.2147/NDT.S241749. PMID: 32606697. PMCID: PMC7292261. (**Impact factor: 2.99; Cited by 2; Altmetric score: 5**).

48. Chang C-Y(g), Park H, Malone DC, Wang C-Y(g), Wilson DL, Yeh Y-M, Boemmel-Wegmann SV(g), **Lo-Ciganic W**. Immune checkpoint inhibitors and risk of immune-related adverse events among patients with advanced melanoma: a systematic review and network meta-analysis. JAMA Netw Open. 2020; 3(3):e201611. PMID: 32211869. PMCID: PMC7097702. DOI: 10.1001/jamanetworkopen.2020.1611. (**Impact factor: 13.37; Cited by 58; Altmetric score: 18**).

49. Chien HS(p), Kao Yang YH, Kwoh CK, Chalasani P, Wilson D, **Lo-Ciganic W**. Aromatase inhibitors and risk of arthritis and carpal tunnel syndrome among Taiwanese women with breast cancer: a nationwide claims data analysis. J Clin Med. 2020; 9(2)pii:E566. PMID: 32092973. PMCID:32092973. DOI: 10.3390/jcm9020566. (**Impact factor: 4.96; Cited by 8; Altmetric score: 5**).

50. Shen Y(g), **Lo-Ciganic W**, Segal R, Goodin AJ. Prevalence of substance use disorder and psychiatric comorbidity burden among pregnant women with opioid use disorder in a large

administrative database, 2009-2014. J Psychosom Obstet Gynaecol. 2020; 18:1-7. PMID: 32067526. DOI: 10.1080/0167482X.2020.1727882. (**Impact factor: 3.23; Cited by 18; Altmetric score: 4**).

51. Chalasani R(g), **Lo-Ciganic W**, Huang JL, Guo J(p), Weiss JC, Kuza CC, Gellad WF. Occupational patterns of opioid-related overdose deaths among Arizona Medicaid enrollees, 2008-2017. J Gen Intern Med. 2020;35(7):2210-2213. PMID: 32043261. PMCID: PMC7352014. DOI: 10.1007/s11606-020-05684-7. (**Impact factor: 6.47; Cited by 2; Altmetric score: 7)**.

52. Dawwas GK(g), Smith S, Dietrich E, **Lo-Ciganic W**, Park H. Comparative effectiveness and safety of apixaban compared to warfarin in patients with venous thromboembolism. Am J Health Syst Pharm. 2020; 77(3):188-195. PMID: 31974557. DOI: 10.1093/ajhp/zxz307. (**Impact factor: 2.98; Cited by 15; Altmetric score: 2**).

53. Zhou L(g), Bhattacharjee S, Kwoh CK, Tighe PJ, Malone DC, Slack M, Wilson DL, Brown JD, **Lo-Ciganic W**. Trends, patient and prescriber characteristics in gabapentinoid use in a sample of United States ambulatory care visits from 2003 to 2016. J Clin Med. 2019; 9(1)pii: E83. PMID: 31905718. PMCID: PMC7019734. DOI: 10.3390/jcm9010083. (**Impact factor: 4.96; Cited by 29; Altmetric score: 4**).

54. Lobo C(g), Cochran G, Chang, C-C, Gellad WF, Gordon AG, Jalal H, **Lo-Ciganic W**, Karp JF, David K, Donohue JM. Associations between the specialty of opioid prescribers and opioid addiction, misuse and overdose outcomes. Pain Med. 2019; pii: pnz234. PMID: 31626295. DOI:10.1093/pm/pnz234. (**Impact factor: 3.64; Cited by 3; Altmetric score: 8**).

55. Metes ID(g), Xue L, Chang CH, Huskamp HA, Gellad WF, Zhang R, **Lo-Ciganic W**, Choudhry NK, Richards-Shubik S, Guclu H, Donohue JM. Association between physician adoption of a new oral antidiabetic medication and Medicare and Medicaid drug spending. BMC Health Serv Res. 2019; 19(1):703. PMID: 31619229. PMCID: PMC6794771. DOI:10.1186/s12913-019-4520-4. (**Impact factor: 2.91; Cited by 1; Altmetric score: 2**).

56. Wei Y-J, Chen C(g), Schmidt SO, **Lo-Ciganic W**, Winterstein AG. Trends in prior receipt of prescription opioid or adjuvant analgesics among patients with incident opioid use disorder or opioid-related overdose. Drug Alcohol Depend. 2019; 204:107600. PMID: 31586806. PMCID: PMC6927577. DOI:10.1016/j.drugalcdep.2019.107600. (**Impact factor: 4.85; Cited by 10; Altmetric score: N/A**).

57. Zhou L(g), Kwoh CK, Ran D, Ashbeck EL, **Lo-Ciganic W**. Lack of evidence that beta blocker use reduces knee pain, areas of joint pain, or analgesic use among individuals with symptomatic knee osteoarthritis. Osteoarthr Cartil. 2020; 28(1):53-61. PMID: 31526877. DOI:10.1016/j.joca.2019.08.008 (**Impact factor: 7.51; Cited by 8; Altmetric score: 10**).

58. Bhattacharjee S, Patanwala AE, **Lo-Ciganic W**, Malone DC, Lee JK, Knapp SM, Warholak T, Burke, WJ. Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: a retrospective cohort study. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2019; 5:294-302. PMID: 31338414. PMCID: PMC6626065. DOI:10.1016/j.trci.2019.05.005. (**Impact factor: 7.10; Cited by 18; Altmetric score: 13**).

59. Donohue JM, Kennedy J, Seymour CW, Girard TD, **Lo-Ciganic W**, Kim CH, Marroquin OC, Moyo P, Chang C-H, Angus DC. Patterns of opioid administration among opioid-naïve inpatients and associations with postdischarge opioid use: a cohort study. Ann Intern Med. 2019; 171(2):81-90. PMID: 31207646. PMCID: PMC6815349. DOI:10.7326/M18-2864. (**Impact factor: 51.60; Cited by 53; Altmetric score: 209**).

60. Bhattacharjee S, Lee JK, Patanwala AE, Vadiei N, Malone DC, Knapp S, **Lo-Ciganic W**, Burke WJ. Extent and predictors of potentially inappropriate antidepressant use among older adults with dementia and major depressive disorder. Am J Geriatr Psych. 2019; 27(8):794-805. PMID: 30926273. PMCID: PMC6646083. DOI:10.1016/j.jagp.2019.02.002. (**Impact factor: 8.00; Cited by 10; Altmetric score: 1**).

61. **Lo-Ciganic W,** Huang JL, Zhang HH, Weiss JC, Wu Y, Kwoh CK, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kuza CC, Gellad WF. Evaluation of machine-learning algorithms for predicting opioid overdose risk among Medicare beneficiaries with opioid prescriptions. JAMA Netw Open. 2019; 2(3):e190968. PMID: 30901048. PMCID: PMC6646083. DOI:10.1001/jamanetworkopen.2019.0968. (**Impact factor: 13.37; Cited by 146; Altmetric score: 137)**.

62. Donohue JM, Guclu H, Gellad WF, Chang CH, Huskamp HA, Choudhry NK, Zhang R, **Lo-Ciganic W**, Junker SP, Anderson T, Richards-Shubik S. Influence of peer networks on physician adoption of new drugs. PLoS One. 2018; 13(10):e0204826. PMID: 30273368. PMCID: PMC6166964. DOI:10.1371/journal.pone.0204826. **(Impact factor: 3.75; Cited by 40; Altmetric score: 18)**.

63. **Lo-Ciganic W**, Donohue JM, Kim JY, Krans EE, Jones B, Kelley D, James E, Jarlenski M. Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States. Pharmacoepidemiol Drug Saf. 2019; 28(1):80-89. PMID: 30192041. PMCID: PMC6557135. DOI:10.1002/pds.4647. **(Impact factor: 2.73; Cited by 42; Altmetric score: 4)**.

64. Cochran G, **Lo-Ciganic W**, Gellad WF, Gordon AJ, Cole E, Chang C, Lobo C(g), Frazier W, Zheng P, Chang C-C, Kelley D, Donohue JM. Prescription opioid quality measures applied among Pennsylvania Medicaid enrollees. J Manag Care Spec Pharm. 2018; 24(9):875-885. PMID: 30156454. PMCID: PMC6418411. DOI:10.18553/jmcp.2018.24.9.875. **(Impact factor: 3.02; Cited by 16; Altmetric score: 6)**.

65. Anderson TS, **Lo-Ciganic W,** Gellad WF, Zhang R, Huskamp HA, Choudhry NK, Chang C-H, Richards-Shubik S, Guclu H, Donohue JM. Patterns and predictors of physician adoption of new cardiovascular drugs. Healthc (Amst). 2018; 6(1):33-40. PMID: 29066168. PMCID: PMC5910251. DOI: 10.1016/j.hjdsi.2017.09.004. **(Impact factor: 2.01; Cited by 22; Altmetric score: 2)**.

66. Hill MG, Gonzalez MG(p), **Lo-Ciganic W**, Reed KL. Misoprostol in addition to a double balloon catheter for induction: a double-blind randomized controlled trial. Am J Perinatol. 2018: 35(3):225-232. PMID: 28910848. DOI: 10.1055/s-0037-1606606. (**Impact factor: 3.08; Cited by 9; Altmetric score: 11)**.

67. Frazier W, Cochran G, **Lo-Ciganic W**, Gellad WF, Gordon AJ, Chang CC, Donohue JM. Medication-assisted treatment and opioid use before and after overdose in Pennsylvania Medicaid. JAMA. 2017; 318(8):750-752. PMID: 28829862. PMCID: PMC5817478. DOI: 10.1001/jama.2017.7818. **(Impact factor: 157.38; Cited by 67; Altmetric score: 307)**.

68. Cochran G, Gordon AJ, Gellad WF, Chang C-C, **Lo-Ciganic W**, Lobo C(g), Cole E, Frazier W, Zheng P, Kelley D, <u>Donohue JM</u>. Medicaid prior authorization and opioid medication abuse and overdose. Am J Manag Care. 2017; 23(5):e164-e171. PMID: 28810127. PMCID: PMC6719534. **(Impact factor: 3.25; Cited by 27; Altmetric score: N/A)**.

69. Almutairi A(g), Zhou L(g), Gellad WF, Lee JK, Slack M, Martin JR, **<u>Lo-Ciganic W</u>**. Effectiveness and safety of non-Vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clin Ther. 2017; 39(7):1456-1478. PMID: 28668628. DOI:10.1016/j.clinthera.2017.05.358. **(Impact factor: 3.64; Cited by 156; Altmetric score: 22)**.

70. **<u>Lo-Ciganic W</u>**, Floden L, Lee JK, Ashbeck EL, Zhou L(g), Chinthammit C(g), Purdy AW, Kwoh CK. Analgesic use and risk of recurrent falls in patients with or at risk of knee osteoarthritis: data from the Osteoarthritis Initiative. Osteoarthr Cartil. 2017; 25(9):1390-1398. PMID: 28385483. PMCID: PMC5989560. DOI: 10.1016/j.joca.2017.03.017. **(Impact factor: 7.51; Cited by 52; Altmetric score: 46)**.

71. Cochran G, Gordon AJ, **Lo-Ciganic W**, Gellad WF, Frazier W, Lobo C(g), Zheng P, <u>Donohue JM</u>. An examination of claims-based predictors of overdose from a large Medicaid program. Med Care. 2017; 55(3):291-298. PMID: 27984346. PMCID: PMC5309160. DOI: 10.1097/MLR.0000000000000676. **(Impact factor: 3.18; Cited by 61; Altmetric score: 4)**.

72. **<u>Lo-Ciganic W</u>,** Donohue JM, Jones BL, Perera S, Thorpe JM, Thorpe CT, Marcum ZA, Gellad WF. Trajectories of diabetes medication adherence and hospitalization risk: a retrospective cohort study in a large state Medicaid program. J Gen Intern Med. 2016; 31(9):1052-1060. PMID: 27229000. PMCID: PMC4978686. DOI: 10.1007/s11606-016-3747-6. **(Impact factor: 6.47; Cited by 70; Altmetric score: N/A)**.

73. Gordon AJ, **Lo-Ciganic W**, Cochran G, Gellad WF, Cathers T, <u>Donohue JM</u>. Treatment quality for buprenorphine care: the pot at the end of the rainbow. [In Reply to "Measurement Quality of Buprenorphine Care"]. J Addict Med. 2016; 10(3):210-211. PMID: 27223837. DOI: 10.1097/ADM. 0000000000000210. (**Impact factor: 4.65; Cited by 6; Altmetric score: 4)**.

74. **<u>Lo-Ciganic W</u>**, Gellad WF, Huskamp HA, Choudhry NK, Chang CH, Zhang R, Jones BL, Guclu H, Richards-Shubik S, <u>Donohue JM</u>. Who were the early adopters of dabigatran? An application of group-based trajectory models. Med Care. 2016; 54(7):725-732. PMID: 27116109. PMCID: PMC4907845. DOI: 10.1097/MLR.0000000000000549. **(Impact factor: 3.18; Cited by 27; Altmetric score: 23)**.

75. <u>Zgibor JC</u>, Schlenk EA, Vater LB, Kola S, Vander Bilt J, Woody SE, Jacob ME, **Lo-Ciganic W**, Brenckle A, Brandenstein J, Kwoh CK, Boudreau R, Albert SM, Conroy MB, Rodger E, Newman AB. Partnership building and implementation of an integrated healthy-aging program. Prog Community Health Partnersh. 2016; 10(1):123-132. PMID: 27018361. PMCID: PMC5988248. DOI: 10.1353/cpr.2016.0001. **(Impact factor: 1.28; Cited by 12; Altmetric score: 1)**.

76. <u>Jacob ME</u>, **Lo-Ciganic W**, Schlenk EA, Terhost L, Vander Bilt J, Zgibor JC, Simkin-Silverman L, Albert SM, <u>Newman AB</u>. The preventive services use self-efficacy (PRESS) scale in older women: development and psychometric properties. BMC Health Serv Res. 2016; 16(1):71. PMID: 26897364. PMCID: PMC4761175. DOI: 10.1186/s12913-016-1321-x. **(Impact factor:**

2.91; Cited by 9; Altmetric score: N/A).

77. **Lo-Ciganic W,** Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, <u>Donohue JM</u>. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016; 111(5):892-902. PMID: 26662858. DOI: 10.1111/add.13270. **(Impact factor: 7.26; Cited by 91; Altmetric score: 11)**.

78. <u>Gordon AJ</u>, **Lo-Ciganic W,** Cochran G, Gellad WF, Cathers T, Kelley D, Donohue JM. Patterns and quality of buprenorphine opioid agonist treatment in a large Medicaid program. J Addict Med. 2015; 9(6):470-477. PMID: 26517324. DOI:10.1097/ADM.0000000000000164. **(Impact factor: 4.65; Cited by 58; Altmetric score: 15)**.

79. <u>Schlenk EA</u>, Vander Bilt J, **Lo-Ciganic W,** Jacob ME$_{(g)}$, Woody SE, Zgibor JC, Conroy MB, Kwoh CK, Albert SM, Bayles CM, Simkin-Silverman L, Boudreau R, <u>Newman AB</u>. Pilot enhancement of the Arthritis Foundation exercise program with a healthy aging program. Res Gerontol Nurs. 2016; 9(3):123-132. PMID: 26501346. PMCID: PMC5861714 DOI: 10.3928/19404921-20151019-04. **(Impact factor: 1.64; Cited by 4; Altmetric score: 3)**.

80. **Lo-Ciganic W,** Donohue JM, Thorpe JM, Perera S, Thorpe CT, Marcum ZA, <u>Gellad WF</u>. Using machine learning to examine medication adherence thresholds and risk of hospitalization. Med Care. 2015; 53(8):720-728. PMID: 26147866. PMCID: PMC4503478. DOI:10.1097/MLR.0000000000000394. **(Impact factor: 3.18; Cited by 78; Altmetric score: 4)**.

81. Minlikeeva A$_{(g)}$, Freudenheim JL, **Lo-Ciganic W,** Eng KH, Friel GL, Diergaarde B, Modugno F, Cannioto RA, Gower E, Szender JB, Grzankowski K, Odunsi K, Ness RB, <u>Moysich KB</u>. Use of common analgesics is not associated with ovarian cancer survival. Cancer Epidemiol Biomarkers Prev. 2015; 24(8):1291-1294. PMID: 26063476. PMCID: PMC4526413. DOI: 10.1158/1055-9965.EPI-15-0508. **(Impact factor: 4.09; Cited by 9; Altmetric score: 1)**.

82. <u>Cochran G</u>, Woo B, **Lo-Ciganic W,** Gordon AJ, Donohue JM, Gellad WF. Defining nonmedical use of prescription opioids within health care claims: a systematic review. Subst Abus. 2015; 36(2):192-202. PMID: 25671499. PMCID: PMC4736503. DOI: 10.1080/08897077.2014.993491. **(Impact factor: 2.34; Cited by 39; Altmetric score: 1)**.

83. **Lo-Ciganic W,** Perera S, Gray SL, Boudreau RM, Zgibor JC, Strotmeyer ES, Donohue JM, Bunker CH, Newman AB, Simonsick EM, Bauer DC, Satterfield S, Caserotti P, Harris T, Shorr RI, <u>Hanlon JT</u>. Statin use and decline in gait speed in community-dwelling older adults. J Am Geriatr Soc. 2015; 63(1):124-129. PMID: 25537649. PMCID: PMC4300263. DOI: 10.1111/jgs.13134. **(Impact factor: 7.54; Cited by 14; Altmetric score: 3)**.

84. <u>Trabert B</u>, Ness RB, **Lo-Ciganic W,** Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagel CM, Jordan SJ, Risch HA, Rossing MA, Doherty JA, Goodman MT, Lurie G, Kier SK, Hogdall E, Jensen A, Cramer DW, Terry KL, Vitonis A, Bandera EV, Olson S, King MG, Chandran U, Anon-Culver H, Ziogas A, Menon U, Gayther SA, Ramus, SJ, Gentry-Maharai A, Wu AH, Pearce CL, Pike MC, Berchuck A, Schildkraut JM, Wentzensen NW. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014: 106(2):djt43. PMID: 24503200. PMCID: PMC3924755. DOI: 10.1093/jnci/djt431. **(Impact factor: 11.82; Cited by 235; Altmetric score: 198)**.

85. **Lo-Ciganic W**, Boudreau RM, Gray SL, Zgibor JC, Donohue JM, Perera S, Newman AB, Simonsick EM, Bauer DC, Satterfield S, <u>Hanlon JT</u> for the Health ABC Study. Changes in

cholesterol-lowering medications use over a decade in community-dwelling older adults. Ann Pharmacother. 2013; 47(7-8): 984-992. PMID: 23780807. PMCID: PMC3707940 DOI: 10.1345/aph.1S050. **(Impact factor: 3.15; Cited by 19; Altmetric score: 1)**.

86. Terry KL, Karageorgi S, Shyestoy YB, Merritt MA, Vitonis AF, Lurie G, Thompson PJ, Carney ME, Weber RP, Akushevick L, **Lo-Ciganic W,** Cushing-Haugen K, Sieh W, Moysich K, Doherty JA, Nagle CM, Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group, Berchuck A, Pearce CL, Pike M, Ness RB, Webb PM, Rossing MA, Schildkraut J, Risch H, Goodman MT on behalf of the Ovarian Cancer Association Consortium. Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res. 2013; 6(8):811-821. PMID: 23761272. PMCID: PMC3766843. DOI: 10.1158/1940-6027.CAPR-13-0037. **(Impact factor: 3.49; Cited by 104; Altmetric score: 426)**.

87. **Lo-Ciganic W,** Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB. Aspirin, non-aspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology. 2012; 23(2):311-319. PMID: 22252409. PMCID: PMC3454462. DOI: 10.1097/EDE.0b013e3182456ad3. (**Impact factor: 4.82; Cited by 69; Altmetric score: 12)**.

88. **Lo-Ciganic W,** Zgibor JC, Ruppert K, Arena V, and Stone RA. Identifying type 1 and type 2 diabetic cases using administrative data: a tree-structured model. J Diabetes Sci Technol. 2011; 5(3):486-493. PMID: 21722564. PMCID: PMC3192615. DOI: 10.1177/193229681100500303. **(Impact factor: 3.12; Cited by 38; Altmetric score: N/A)**.

89. **Lo W,** Kao Yang YH, and Sung JM. Antihypertensive agents and new-onset diabetes. Kidney and Dialysis. 2004; 16:225-240. (Chinese).

90. **Lo W,** Li YH, and Lin CY. Selective serotonin reuptake inhibitors (SSRI). National Cheng Kung University Pharmacy Forum. 2004; 14(6). (Chinese).

Reviews, Reports, Proceedings, Books and Book Chapters

1. **Lo-Ciganic W** and Hincapie-Castillo JM. "Chapter 20: Systematic reviews and meta-analysis in pharmacy." In Aparasu RR, Bentley JP, and Pate AN: Student Handbook for Pharmacy Practice Research. A Companion Book to Conduct Practice-Based Research in Pharmacy. 1st Ed. McGraw Hill; June 30, 2022. ISBN-10: 1260474259

2. **Lo-Ciganic W,** Donohue JM, Cole E, Gellad WF. Report on characteristics of Pennsylvania Medicaid beneficiaries receiving new oral direct antiviral agents for hepatitis C infections: 2013-2015. Report to the Office of Medical Assistance Programs in the Pennsylvania Department of Human Services. The Medicaid Research Center, University of Pittsburgh, PA, April 2017.

3. **Lo-Ciganic W,** Donohue JM, Kim JY, Krans EE, Cole E, Jarlenski M. Report on adherence trajectories of buprenorphine therapy among pregnant women: 2008-2015. Report to the Office of Medical Assistance Programs in the Pennsylvania Department of Human Services. The Medicaid Research Center, University of Pittsburgh, PA, April 2017.

4. Donohue JM, Cole E, Kim J-Y, Zheng P, **Lo-Ciganic W,** Gordon AJ, Gellad WF, Cochran G. Report of opioid prescribing quality measures, opioid use, opioid use disorder and medication-

assisted treatment in Pennsylvania Medicaid. Report to the Office of Medical Assistance Programs in the Pennsylvania Department of Human Services. The Medicaid Research Center, University of Pittsburgh, PA, March 2017.

5.   **Lo-Ciganic W,** Humble W, Roubal A, Wightman P, Butler M, Calhoun E. Emergency department and inpatient visits for substance use disorders in Arizona. 2015 The University of Arizona Health Sciences Center Policy Briefs Vol 1.
https://pophealth.uahs.arizona.edu/sites/default/files/uploads/issue_brief_vol_1_issue_1.pdf
(Access Date: 11/29/2017)

6.   Donohue JM, **Lo-Ciganic W**, Cochran G, Gordon AJ, Zemaitis MA, Gellad WF. Report on opioid use, opioid use disorder and buprenorphine use in Pennsylvania Medicaid. Report to the Department of Public Welfare, Office of Medical Assistance Programs, March 2014.

7.   Kuller L, **Lo-Ciganic W,** Buchanich J, Sharma R. Report of the Allegheny County Mortality and Health Improvement Project: Analysis of mortality data and recommendations. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, PA, March 2012.

Refereed Podium or Symposium Presentations
Keys to indicate author relationship: self=bold; presenting author =underline; fellow =f; graduate student =g; post-doctoral associate/fellow =p; resident =r

1.   Park H, **Lo-Ciganic W**, Huang J, Wu Y, Wilson D, Henry L, Peter J, Sulkowski M, Nelson DR. Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection. Asian Pacific Association for the Study of the Liver Single Topic Conference (APASL STC) 2023, Busan, Korea, September 2023.

2.   Kuza C, **Lo-Ciganic W**, Barnes S, Huang J, FedroByrom S, Guo J, Hulsey E, Dauria E, Yang Q, Donohue J, Parker L, Liebschutz J, Gellad W. Development of a machine-learning algorithm to predict fatal opioid overdose among individuals released from jail. 2023 AcademyHealth Annual Research Meeting (ARM), Seattle, WA, USA, June 2023.

3.   Lewis MO$_{(g)}$, Zhou L$_{(g)}$, Gellad W, Hincapie-Castillo JM, Wilkie D, Segal R, Wilson D, **Lo-Ciganic W**. Geographic variation of high-risk prescription opioid measures among disabled Medicare beneficiaries, 2011-2018. Annual Biomedical Research Conference for Minoritized Scientists, Anaheim, CA, USA, November 2022.
    • UF College of Pharmacy Charlotte Liberty Fund Awardee

4.   Chang CY$_{(g)}$, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, Wilson DL, **Lo-Ciganic W**. Association between trajectories of prescription opioid use and risk of opioid use disorder or overdose among Nonmetastatic breast cancer survivors. 2022 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Copenhagen, Denmark, August 2022.

5.   Chang CY$_{(g)}$, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, Wilson DL, **Lo-Ciganic W**. Association between trajectories of adherence to endocrine therapy and risk of breast cancer recurrence among nonmetastatic breast cancer survivors. 2022 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Copenhagen, Denmark, August 2022.

6. Hincapie-Castillo JM, Gellad WF, Jones BL, Huang JL, Chang CY(g), Wilson DL, Resifield G, Kwoh CK, Nguyen K, Delcher C, Harle CA, Ge Y, Shorr R, Marcum ZA, Yang S, Huang PL, Adkins L, **Lo-Ciganic W**. Dosing profiles of opioid and benzodiazepine use associated with risk of injurious falls among US Medicare beneficiaries: group-based multi-trajectory models. 2022 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Copenhagen, Denmark, August 2022.

7. Lewis MO(g), Zhou L(g), Gellad W, Hincapie-Castillo JM, Wilkie D, Segal R, Wilson D, **Lo-Ciganic W**. Geographic variation of high-risk prescription opioid use measures among disabled Medicare beneficiaries, 2011-2018. 2022 Pharmacy Quality Alliance Annual Meeting, Baltimore, MD, USA, May 2022.
    - Best Student Poster Award

8. Lewis MO(g), Zhou L(g), Gellad W, Hincapie-Castillo JM, Wilkie D, Segal R, Wilson D, **Lo-Ciganic W**. Geographic patterns of prescription opioid use in disabled Medicare beneficiaries. UF College of Pharmacy 35th Annual Research Showcase, Gainesville, FL, USA, February 2022.

9. Kang H(p), Huang PL, **Lo-Ciganic W**, Park H, DeRemer C, Dietrich E. Effectiveness and safety of extended anticoagulation for venous thromboembolism. 34th University of Florida College of Pharmacy Annual Research Showcase, Gainesville, FL, USA, August 2021.

10. **Lo-Ciganic W**, Wang T, Ge Y, Jones B, Huang J, Reisfield G, Lee J, Kwoh K, Hincapie-Castillo JM, Delcher C, Chang CY(g), Wilson D, Gellad W. Association between dose and duration patterns of opioid and benzodiazepine use and risk of overdose among US Medicare beneficiaries: a group-based multi-trajectory model. Pharmacoepidemiol Drug Saf. 2020;29(Suppl. 3):5. (Oral Presentation at the 2020 Virtual 36th International Conference on Pharmacoepidemiology and Therapeutic Risk Management).

11. **Lo-Ciganic W**, Wang T, Ge Y, Jones B, Huang J, Reisfield GM, Lee JK, Kwoh CK, Hincapie-Castillo JM, Delcher C, Chang CY(g), Wilson D, Gellad W. PMH26. Association between dose and duration patterns of opioid and benzodiazepine use and risk of overdose among US Medicare beneficiaries: a group-based multi-trajectory model. Value in Health. 2020; 23: S204-S205.2020 ISPOR Virtual Conference

12. Chang C-Y(g), Hincapie-Castillo JM, Wilson DL, **Lo-Ciganic W**. Evaluation of concurrent use of opioids with high-risk medications among Arizona Medicaid beneficiaries: cross-sectional analysis from 2011 to 2017. Pharmacoepidemiol Drug Saf. 2020;29(Suppl. 3):643. 2020 Mid-Year ISPE meeting *canceled due to COVID-19

13. Yeh W-H, Sheinson D, Marquez A, **Lo-Ciganic W**. Making machine learning a reality for HEOR-practical applications to real-world studies. 2020 ISPOR, May 2020 (presented virtually due to COVID-19).

14. Goodin A, Huang J, Park H, Skvarla D, Hincapie-Castillo JM, **Lo-Ciganic W**. Controlled substance prescription utilization trends in Arizona from 2011-2016, by prescription class. In: Garets M, Archer S, Kitchens C, Cochran G, Gordon AJ. The 2019 Addiction Health Services Research Conference: Insights, review, and abstracts. Subst Abus. 2019;40(4):469-472 (Supp 113). 2019 Addiction Health Services Research Conference, Park City, UT, USA, October 2019.

15. Goodin AJ, Huang JL, Park H, Hincapie-Castillo JM, Brown JD, Costales B(g), **Lo-Ciganic W**. Change in buprenorphine prescriptions for opioid use disorder indications in Arizona from 2011-2016. 2019 Addiction Health Services Research Conference, Park City, UT, USA, October

2019.

16.   Marcum ZA, Chang C-Y(g), **Lo-Ciganic W**. Association between pharmaceutical industry payments and prescribing a fixed-dose combination memantine extended released and donepezil: a cross-sectional study. Poster Spotlight presentation at the 2019 Asian Conference on Pharmacoepidemiology [ACPE], Kyoto, Japan, October 2019.

17.   Tan T, Zhou L(g), Bell M, **Lo-Ciganic W**. Racial minorities were associated with less prescription opioids use following lower extremity amputation in Medicare. 2019 4th Society of Asian Academic Surgeons (SAAS) annual meeting, Boston, MA, USA, September 2019. (Quick shots presentation)

18.   Yao R, Li Q, **Lo-Ciganic W**, Zeng D. A prior knowledge based neural attention model for opioid topic identification. 2019 IEEE International Conference on Intelligence and Security Informatics (ISI) 17th Annual Conference. Shenzhen, China, July 2019.

19.   Zhou L(g), Bhattacharjee S, Kwoh CK, Tighe PJ, Reisfield GM, Malone DC, Slack M. **Lo-Ciganic W**. Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among United States Medicare beneficiaries. 2019 ICPE 35th Annual Conference, Pennsylvania, PA, USA, August 2019.

20.   **Lo-Ciganic W**, Huang JL, Zhang HH, Weiss JC, Wu Y, Kwoh CK, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kuza CC, Gellad WF. Using machine learning to predict risk of opioid overdose in fee-for-service Medicare. 2019 ICPE 35th Annual Conference, Philadelphia, PA, USA, August 2019.

21.   Zhou L(g), Bhattacharjee S, Kwoh CK, Tighe PJ, Reisfield GM, Malone DC, Slack M. **Lo-Ciganic W**. Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among United States Medicare beneficiaries. 2019 ISPOR 24th Annual International Meeting, New Orleans, LA, USA, May 2019.
    * Student presentation spotlight (only 8 students were selected).

22.   Yao R, Li Q, Zeng DD, **Lo-Ciganic W**. Identifying topics of opioid use discussion using an unsupervised neural attention model. 2018 Institute of Electrical and Electronics Engineers (IEEE) Intelligence and Security Informatics (ISI), Miami, FL, USA, November 2018.

23.   **Lo-Ciganic W**, Kwoh CK, Huang JL, Zhang H, Donohue JM, Gordon AJ, Malone DC, Cochran G, Gellad WF. Using machine learning to predict risk of opioid overdose in fee-for-service Medicare. 2018 Addiction Health Service Research (AHSR) Annual Conference, Savannah, GA USA, October 2018.

24.   **Lo-Ciganic W**, Gellad WF, Zhou L(g), Donohue JM, Roubal A, Hines L, Lindemann J, Malone DC, Bhattacharjee S, Lee JK, Kwoh CK. Geographic variation of high-risk opioid use and risk of overdose among disabled Medicare beneficiaries in the US from 2011-2015. 2018 34th ICPE Annual Conference, Prague, Czech Republic, August 2018.

25.   **Lo-Ciganic W**, Gellad WF, Zhou L(g), Donohue JM, Roubal A, Hines L, Lindemann J, Malone DC, Bhattacharjee S, Lee JK, Kwoh CK. Geographic variation of high-risk opioid use and risk of overdose among disabled Medicare beneficiaries in the US from 2011-2015. 2018 ISPOR 23rd Annual International Meeting, Baltimore, MA, USA, May 2018.

26.   Chien H-C(p), **Lo-Ciganic W**, Kwoh CK, Kao-Yang Y-H. Use of aromatase inhibitors and risk of arthralgia among Taiwanese breast cancer women: a nation-wide claims analysis. 2017 American College of Rheumatology (ACR) Annual Conference, San Diego, CA, USA,

November 2017.

27. Sudano DG, <u>Kowh CK</u>, Zhou L$_{(g)}$, Ashbeck EL, **Lo-Ciganic W**. Use of disease-modifying anti-rheumatic drugs, biologic response modifiers and corticosteroids, and subsequent risk of coccidioidomycosis infection among Medicare beneficiaries. 2017 American College of Rheumatology (ACR) Annual Conference, San Diego, CA, USA, November 2017.

28. **Lo-Ciganic W**, Donohue JM, Kim JY, Krans EE, Kelley D, James E, Jarlenski M. Trajectories of buprenorphine opioid agonist therapy during pregnancy in a large Medicaid program. 2017 International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, Canada, August 2017.

29. <u>Cochran G</u>, Gordon AJ, Gellad WF, Chang C, **Lo-Ciganic W**, Lobo C$_{(g)}$, Cole E, Frazier W, Zheng P, Kelley D, Donohue JM. The influence of prior authorization policies on opioid medication abuse and overdose among members of a large Medicaid program. 2017 College on Problems of Drug Dependence (CPDD), Montreal, Canada, June 2017.

30. Zhou L$_{(g)}$, Kwoh CK, Gellad WF, Donohue JM, Roubal A, Hines L, Malone DC, Bhattacharjee S, Lee JK, Lindemann J, Bell M, Westra J$_{(g)}$, **Lo-Ciganic W**. Geographic variation of inappropriate prescription opioid use among disabled Medicare beneficiaries. 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting, Boston, MA, USA, May 2017.

31. **Lo-Ciganic W,** Donohue JM, Jones BL, Perera S, Thorpe JM, Thorpe CT, Marcum ZA, Gellad WF. Trajectories of diabetes medication adherence and hospitalization risk. 2015 International Conference on Pharmacoepidemiology and Therapeutic & Risk Management (ICPE), Dublin, Ireland, August 2016 (**Poster Spotlight Presentation**).

32. **Lo-Ciganic W,** Donohue JM, Thorpe JM, Perera S, Thorpe CT, Marcum ZA, Gellad WF. Using machine learning to examine medication adherence thresholds and risk of hospitalization. 2015 International Conference on Pharmacoepidemiology and Therapeutic & Risk Management, Boston, MA, USA, August 2015.

33. **Lo-Ciganic W,** Gellad WF, Gordon AJ, Cochran G, Donohue JM. Trajectories of buprenorphine treatment and associated emergency department and inpatient use in a large Medicaid program. 2015 International Conference on Pharmacoepidemiology and Therapeutic & Risk Management (ICPE), Boston, MA, USA, August 2015.

34. **Lo-Ciganic W,** Donohue JM, Thorpe JM, Perera S, Thorpe CT, Marcum ZA, Gellad WF. Using machine learning to examine medication adherence thresholds and risk of hospitalization. 2015 Conference on the Science of Medication Adherence, Pittsburgh, PA, USA, June 2014.

35. **Lo-Ciganic W,** Gellad WF, Gordon AJ, Cochran G, Donohue JM. Trajectories of buprenorphine treatment and associated emergency department and inpatient use in a large Medicaid program. 2015 Conference on the Science of Medication Adherence, Pittsburgh, PA, USA, June 2014.

36. <u>Cochran G</u>, Woo B, Donohue JM, Gordon AJ, **Lo-Ciganic W,** Gellad WF. Defining non-medical use of prescription opioids within health insurance claims data: a systematic review. 2014 Association for Medical Education and Research in Substance Abuse (AMERSA) National Conference, San Francisco, CA, USA, November 2014.

37. <u>Schlenk EA</u>, Vander Bilt J, **Lo-Ciganic W,** Woody SE, Zgibor JC, Conroy MB, Kwoh CK, Newman AB. Integration of a healthy aging program into the Arthritis Foundation Exercise

Program: six-month results. American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (AHRP) Annual Scientific Meeting, Washington, D.C., USA, November 2012.

38.   Vander Bilt J, **Lo-Ciganic W,** Woody SE, Zgibor JC, Conroy MB, Schlenk EA, Newman AB. Integrating a healthy prevention program into a collaborative framework in community-based research. 2012 the 140th American Public Health Association (APHA) Annual Meeting, San Francisco, CA, USA, October 2012 (**Round Table Presentation)**.

39.   Zgibor JC, **Lo-Ciganic W,** Wolf D. Implementing the chronic care model in primary care: impacting outcomes of care. Center for Disease Control Conference, Orlando, FL, USA, December 2011.

40.   **Lo W,** Huang JJ, Kao Yang YH, Guo HR, Kao SM, and Wang MC. Cardiovascular disease and residual renal function in peritoneal dialysis patients: protective roles of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Taiwan Nephrology 2005 Annual Meeting, Taipei, Taiwan, December 2005.

41.   **Lo W,** Wang MC, Kao SM, and Kao Yang YH. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on protection of cardiovascular disease in peritoneal dialysis patients. American College of Clinical Pharmacy 2005 Annual Meeting, San Francisco, CA, USA, October 2005.

Peer-reviewed Abstracts (Published) with Conference Presentations

Keys to indicate author relationship: self=bold; presenting author =underline; fellow =f; graduate student =g; post-doctoral associate/fellow =p; resident =r

1.   Park H, **Lo-Ciganic W**, Huang J, Wu Y, Wilson D, Henry L, Peter J, Sulkowski M, Nelson DR. Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection. Submitted. Asian Pacific Association for the Study of the Liver Single Topic Conference (APASL STC) 2023 [submitted]

2.   Wang GHM$_{(g)}$, Morris EJ, **Lo-Ciganic W**, Vouri SM, Smith SM. Modifiable statin characteristics associated with potential statin-related prescribing cascades in a large commercial insurance claims data of adult statin initiators. (Oral presentation at ISPE 2023 Mid-year Meeting, Reykjavik, April 2023).

3.   Nguyen KA, Diiulio J, Militello L, Wilson DL, Gellad WF, Lewis M$_{(g)}$, Hall B$_{(f)}$, Harle CA, Schmidt S, Nelson D, He X, Qin X, Budd JT, Meenrajan SR, Orlando FA, Pennington JM, Kuza C, Hasan M, Staras SA, Bian J, Wu Y, Weiss JC, Gordon AJ, Cochran J, **Lo-Ciganic W**. Design process for a machine-learning opioid overdose prediction and risk stratification e-tool (DEMONSTRATE). (Oral presentation at 2023 AMIA Clinical Informatics Conference, Chicago, IL, USA, May 2023).

4.   Nguyen K, Diiulio J, Militello L, Wilson DL, Gellad WF, Lewis M$_{(g)}$, Hall B$_{(f)}$, Harle C, Schmidt S, Nelson D, He X, Qin X, Budd JT, Meenrajan SR, Frank A. Orlando FA, Pennington JM, Kuza C, Hasan MM, **Lo-Ciganic W**. Prototype development and algorithm explainability of a machine-learning opioid overdose prediction and risk stratification e-tool (DEMONSTRATE). (Poster presentation at the Transforming Healthcare and Biomedicine for a Sustainable Future, AMIA 2023 Clinical Informatics Conference, Chicago, IL, USA, May 2023).

5.   Yang S$_{(g)}$, Huang S$_{(g)}$, Hincapie-Castillo JM, Ke X, Ding H, Sher MR, Jones B, Wilson DL, **Lo-Ciganic W**. Prescription antitussive use trajectories and their characteristics among patients

with chronic cough in Florida. (Presented at the International Society of Pharmaceutical Outcomes Research (ISPOR) Annual Conference, Boston, MA, USA, May 2023).

6. Gellad W, Hasan MM, Huang PL, Nguyen K, Wilson DL, Harle C, Bian J, Wu Y, Weiss J, Gordon A, Cochran J, DiIulio J, Militello L, Staras S, Budd J, Meenrajan S, Orlando F, Pennington J, Schmidt S, Lewis M(g), Kuza C, Vouri S, **Lo-Ciganic W**. Development and implementation of a machine-learning based opioid overdose risk prediction tool in the electronic health records: current state and challenges. NIDA Symposium Workshop "Data science opportunities and challenges in risk prediction and clinical decision support using electronic health and prescribing data to address substance use-related morbidity and mortality". (Presented at the 2023 AMIA Informatic Summit. Seattle, WA, USA, March 2023).

7. **Lo-Ciganic W**, Hasan MM, Huang P-L, Nguyen K, Wilson DL, Harle CW, Bian J, Wu Y, Weiss JC, Gordon AJ, Cochran G, Dilulio J, Militello L, Staras SAS, Vouri SM, Budd JT, Meenrajan SR, Orlando FA, Pennington JM, Schmidt S, Lewis M(g), Kuza CC, Gellad WF. Developing and evaluating of a machine-learning opioid overdose prediction and risk stratification e-tool (DEMONSTRATE). (Presented at the 2023 AMIA Informatic Summit. Seattle, WA, USA, March 2023).

8. Huang S(g), Yang S(g), Hincapie-Castillo JM, Ke X, Schelfhout J, Ding H, Sher M, Jones B, Wilson DL, **Lo-Ciganic W**. Characteristics of US Medicare beneficiaries with chronic cough vs nonchronic cough: 2011-2018. (Poster presentation at the AMCP Nexus 2022, National Harbor, MD, USA, October 2022).

9. Hincapie-Castillo JM, Gellad WF, Jones BL, Lee JK, Huang JL, Chang CY(g), Wilson DL, Reisfield GM, Kwoh CK, Nguyen KA, Delcher C, Harle CA, Ge Y, Shorr RI, Marcum Z, Yang S(g), Huang PL, Adkins L, **Lo-Ciganic W**. Dosing profiles of opioid and benzodiazepine use associated with risk of injurious falls among US Medicare beneficiaries: group-based multi-trajectory models. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):3-628. DOI: 10.1002/pds.5518. (Presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Copenhagen, Denmark, August 2022).

10. <u>Yang S(g)</u>, Chang CY(g), Hincapie-Castillo JM, Gellad WF, Jones BL, Lee JK, Huang JL, Wilson DL, Reisfield GM, Kwoh CK, Nguyen KA, Delcher C, Harle CA, Ge Y, Shorr RI, Huang PL, Adkins L, **Lo-Ciganic W**. Trajectories of concurrent opioid and benzodiazepine use and associated opioid overdose risk among Arizona Medicaid beneficiaries. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):3-628. DOI: 10.1002/pds.5518. (Presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Copenhagen, Denmark, August 2022).

11. <u>Yang S(g)</u>, Huang S(g), Hincapie-Castillo JM, Ke X, Schelfhout J, Ding H, Sher MR, Wilson DL, **Lo-Ciganic W**. Characteristics and trends in cough medication use among patients with chronic cough in Florida: 2013-2019. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):3-628. DOI: 10.1002/pds.5518. (Presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Copenhagen, Denmark, August 2022).

12. Chang CY(g), Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, Yang S(g), Wilson DL, **Lo-Ciganic W**. Trends and characteristics associated with nonadherence to antidepressants among breast cancer survivors with depression. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):3-628. DOI: 10.1002/pds.5518. (Presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Copenhagen, Denmark, August 2022).

13. Lewis MO(g), Zhou L(g), Gellad W, Hincapie-Castillo JM, Wilkie D, Segal R, Wilson D, **Lo-Ciganic W**. Geographic variation of high-risk prescription opioid measures among disabled Medicare beneficiaries, 2011-2018. Pharmacoepidemiol Drug Saf, 2022;31(S2):50-51. DOI: 10.1002/pds.5518. (Podium presentation at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Copenhagen, Denmark, August 2022).
    - Student Travel Scholarship Award

14. Yang S(g), Orlova Y, Boren M, Lipe A, Wilson DL, **Lo-Ciganic W**. Trends in the management of headache disorders in US Emergency Departments: analysis of National Hospital Ambulatory Medical Care Survey 2007-2018 Data. Headache. 2022;62(Suppl. 1):36. DOI: doi.org/10.1111/head.14317. 2022 (Presentation at American Headache Society (AHS) 64th Annual Scientific Meeting, Denver, CO, USA, June 2022).

15. Lewis MO(g), Zhou L(g), Gellad W, Hincapie-Castillo JM, Wilkie D, Segal R, Wilson D, **Lo-Ciganic W**. Geographic variation of high-risk prescription opioid use measures among disabled Medicare beneficiaries, 2011-2018. Value in Health. 2022;25(7):S501. DOI: 10.1016/j.jval.2022.04.1125. (Poster presentation at the 2022 ISPOR Annual Conference, National Harbor, MD, USA, May 2022).
    - Top 5% Finalist, Best Student Poster Award

16. Yang S(g), Hincapie-Castillo JM, Ke X, Schelfhout J, Ding H, Sher M, Wilson DL, **Lo-Ciganic W**. Evaluation of utilization patterns of cough medications in ambulatory care settings in the United States: 2003-2018. Value in Health. 2022;25(7):S488-S489. DOI: doi.org/10.1016/j.jval.2022.04.1051. (Poster presentation at the 2022 ISPOR Annual Conference, National Harbor, MD, USA, May 2022).

17. Huang S(g), Lewis MO(g), Bao Y, Bian J, Gellad WF, Wu Y, Pathak J, Oslin D, Adkins LE, Yin P(g), Sutton JA, Goodin AJ, Wang F, Banerjee S, Adekkanattu P, Wilson DL, **Lo-Ciganic W**. Predictive modeling for suicide-related outcomes and risk factors among patients with pain conditions: a systematic review. Value in Health, 2022; 25 (7): S327. DOI: ttps://doi.org/10.1016/j.jval.2022.04.220. (Poster presentation at the 2022 ISPOR Annual Conference, National Harbor, MD, USA, May 2022).
    - Top 5% poster finalist

18. Lewis MO(g), Zhou L(g), Gellad WF, Hincapie-Castillo JM, Wilkie DJ, Segal R, Wilson DL, **Lo-Ciganic W**. HSD125 Geographic variation of high-risk prescription opioid use measures among disabled Medicare beneficiaries, 2011-2018. Value in Health. 2022;25(7):S501. DOI: 10.1016/j.jval.2022.04.1125. (Poster presentation at the 2022 Virtual ISPOR annual conference, May 2022).

19. Lewis MO(g), Zhou L(g), Gellad W, Hincapie-Castillo JM, Wilkie D, Segal R, Wilson D, **Lo-Ciganic W**. Geographic variation of high-risk prescription opioid use measures among disabled Medicare beneficiaries, 2011-2018. (Poster presentation at the 2022 Pharmacy Quality Alliance Annual Meeting, Baltimore, MD, USA, May 2022).

20. Lewis MO(g), Zhou L(g), Gellad W, Hincapie-Castillo JM, Wilkie D, Segal R, Wilson D, **Lo-Ciganic W**. Geographic patterns of prescription opioid use in disabled Medicare beneficiaries. (Poster Presentation at the UF College of Pharmacy 35th Annual Research Showcase, Gainesville, FL, USA, February 2022).

21. Yang S(g), Lipe A, Boren M, Hincapie-Castillo JM, Brown JD, Park H, Guo J, Chang C(g), Wilson DL, Adkins L, **Lo-Ciganic W**. Trends in the management of primary headache in US emergency

departments: Analysis of 2007-2018 NHAMCS data. Pharmacoepidemiol Drug Saf. 2021; 30(Supplement 1). https://DOI.org/10.1002/pds.5305. (Poster presentation at the 2021 Virtual 37th ICPE, August 2021).

22. Unigwe I(g), Yang S(s), Song H(p), **Lo-Ciganic W**, Cook R, Park H. Trends in sexually transmitted infections in the United States ambulatory care clinics from 2005-2016. Pharmacoepidemiol Drug Saf. 2021; 30(Supplement 1). https://DOI.org/10.1002/pds.5305. (Poster presentation at the 2021 Virtual 37th ICPE, August 2021).

23. Keshwani S, Brown JD, **Lo-Ciganic W**, Yang S(s), Smolinski NE, Hincapie-Castillo JM. Trends in prescribing of non-steroidal anti-inflammatory medications in the US ambulatory care setting, 2006-2016. Pharmacoepidemiol Drug Saf. 2021; 30(Supplement 1). https://DOI.org/10.1002/pds.5305. (Poster presentation at the 2021 Virtual 37th ICPE, August 2021).

24. Faddoul N, Ravindra N, **Lo-Ciganic W**, Hincapie-Castillo JM, Park H, Heldermon CD, Yang S(g), Wilson DL, Adkins LE, Chang C(g). Opioid use patterns among non-metastatic cancer survivors: a systematic literature review. Pharmacoepidemiol Drug Saf. 2021; 30: p285 (Supplement 1). https://DOI.org/10.1002/pds.5305. (Poster presentation at the 2021 Virtual 37th ICPE, August 2021).

25. Ravindra N, Faddoul N, **Lo-Ciganic W**, Hincapie-Castillo JM, Park H, Heldermon CD, Yang S(g), Wilson DL, Adkins L, Chang C(g). Association between non-adherence to endocrine therapy and the risk of recurrence among breast cancer survivors: a systematic literature review. Pharmacoepidemiol Drug Saf. 2021; 30(Suppl. 1):148-149. doi: doi.org/10.1002/pds.5305. (Poster presentation at the 2021 Virtual 37th ICPE, August 2021).

26. Jiang X (g), Vouri SM, Diaby V, **Lo-Ciganic W**, Parker R, Park H. Healthcare utilization and costs associated with direct-acting antivirals for patients with chronic hepatitis C and substance use disorders. Value in Health. 2021 Jun 1;24:S156. (Poster presentation at the 2021 Virtual ISPOR Annual Conference, May 2021).

27. Jiang X(g), Diaby V, Vouri SM, **Lo-Ciganic W**, Parker R, Wang W, Henry L, Park H. A budget impact analysis of universal hepatitis C virus (HCV) testing for patients with substance use disorders. Value in Health. 2021 Jun 1;24:S147-8. (Poster presentation at the 2021 Virtual ISPOR Annual Conference, May 2021).

28. Yang S(g), Boren M, Lipe A(g), Hincapie-Castillo JM, Joshua DB, Park H, Guo J, Chang C(g), Wilson DL, Adkins EL, **Lo-Ciganic W**. Trends and characteristics in opioid analgesic use for migraine in US Emergency Departments: Analysis of National Hospital Ambulatory Medical Care Survey 2007-2018 Data. Value in Health. 2021; 24:S168 (Poster Presentation at the 2021 Virtual ISPOR Annual Conference, May 2021).

29. Ravindra N(g), Faddoul N(g), **Lo-Ciganic W**, Hincapie-Castillo JM, Park H, Heldermon CD, Yang S(g), Wilson DL, Adkins L, Chang C(g). Association between non-adherence to endocrine therapy and the risk of recurrence among breast cancer survivors: a systematic literature review. Value in Health. 2021; 24:S62. (Poster Presentation at the 2021 Virtual ISPOR Annual Conference, May 2021).

30. Huang S(g), **Lo-Ciganic W**, Shao H. Cost-effectiveness of intensive vs. moderate hypertension treatment in US adults age 65 and older at high risk of atherosclerotic cardiovascular disease. Value in Health. 2021;24:S68. DOI:10.1016/j.jval.2021.04.350. (Presentation at Virtual 2021 International Society of Pharmaceutical Outcomes Research (ISPOR) Annual Conference, May 2021).

- Student Abstract Finalist and Oral Presentation Spotlight

31. <u>Chang C(g)</u>, Hincapie-Castillo JM, Wilson DL, **Lo-Ciganic W.** Trends and patient characteristics in concurrent use of opioids with high-risk medications among Arizona Medicaid beneficiaries, 2011-2017. Pharmacoepidemiol Drug Saf. 2020;29(Suppl. 3):274. (Poster presentation at the 2020 Virtual 36th ICPE, October 2020).

32. <u>Yang S(g)</u>, Hincapie-Castillo JM, Chang C(g), Wilson DL, **<u>Lo-Ciganic W</u>**. Trends and characteristics in cough prescription use in ambulatory care settings in the United States: 2003-2016. Pharmacoepidemiol Drug Saf. 2020;29(Suppl. 3):253. (Poster presentation at the 2020 Virtual 36th ICPE, October 2020).

33. <u>Chang CY(g)</u>, Park H, **Lo-Ciganic WH**. The prevalence of sun protective behaviors across different age groups in the US population: findings from the 2015 US Health Interview Survey. Pharmacoepidemiol Drug Safety. 2020;29(S3):3946. (Poster presentation at the 2020 Virtual 36th ICPE, October 2020).

34. <u>Chang CY(g),</u> Hincapie-Castillo JM, Wilson DL, **Lo-Ciganic WH**. Trends and patient characteristics in concurrent use of opioids with high-risk medications among Arizona Medicaid beneficiaries, 2011-2017. Value Health. 2020;29(Supplement 3):5021. https://DOI.org/10.1002/pds.5114 (Poster presentation at the 2020 ISPOR [conference was canceled due to COVID-19]).

35. <u>Yang S(g)</u>, Hincapie-Castillo JM, Chang C-Y(g), Wilson DL, **Lo-Ciganic W**. Trends and characteristics in cough prescription use in ambulatory care settings in the United States: 2003-2016. Pharmacoepidemiol Drug Saf. 2020;29(Supplement 3):4431. (Poster presentation at the 2020 ICPE [conference was canceled due to COVID-19]).

36. <u>Chen C(g)</u>, Winterstein AG, **Lo-Ciganic W**, Tighe P, Wei Y-J. Prescription gabapentinoid use and opioid-related adverse events in Medicare older adults. Pharmacoepidemiol Drug Saf. 2020;29(S3):4749. https://DOI.org/10.1002/pds.5114 (Presentation at the 2020 ICPE [conference was canceled due to COVID-19]).

37. Goodin A, Huang J, Park H, Hincapie-Castillo JM, Brown J, Costales B(g), Wilson D, **Lo-Ciganic W**. Changes in prevalence of high-risk opioid use quality measures in Arizona, 2011-2018. (Published in conference proceedings; Poster presentation at the 2020 Virtual Annual Research Meeting of Academy Health, June 2020).

38. <u>Hincapie-Castillo JM</u>, Goodin A, Vouri S, **Lo-Ciganic W**, Park H. PDG33 Changes in Schedule II oral opioid volume dispensed in a private payer following Florida's Acute Pain Opioid Restriction Law. Value in Health. 2020; 23:S135. 2020 ISPOR Virtual Conference

39. <u>Tasmim K(g)</u>, Goodin AJ, Lopez-Quintero C, Park H, Mora J, **Lo-Ciganic W**, <u>Hincapie-Castillo JM</u>. Increases in county-level opioid prescribing in the United States despite national declining rates, 2012-2017. Subst Abus. 2020. (in press; Poster presentation at the 2020 College on Problems of Drug Dependence (CPDD), Hollywood, FL, USA, June 2020).

40. <u>Marcum ZA</u>, Chang C-Y(g), Barthold D, Holmes HM, **Lo-Ciganic W**. Association between pharmaceutical industry payments and prescribing of branded memantine and donepezil combination. Value Health. 2020; 23(Supplement 1):S272. (Poster presentation at the 2020 ISPOR [conference was canceled due to COVID-19]).

41. Jiang X(g), Parker R, Vouri SM, **Lo-Ciganic W**, Diaby W, Park H. Hepatitis C testing among Florida Medicaid beneficiaries with substance use disorders. Value Health. 2020; 23(Supplement 1):S209. (Poster presentation at the 2020 ISPOR [conference was canceled due to COVID-19]).

42. Hincapie-Castillo JM, Goodin AJ, Vouri SM, Park H, **Lo-Ciganic W**. Changes in Schedule II oral opioid volume dispensed in a private payer following Florida's acute pain opioid restriction law. Value Health. 2020; 23(Supplement 1):S135. (Poster presentation at the 2020 ISPOR [conference was canceled due to COVID-19]).

43. Song H-J(p), Squires P(g), Wilson DL, **Lo-Ciganic W**, Cook RL, Park H. Uptake of pre-exposure prophylaxis (PREP) and type of providers among commercially-insured persons in the United States, 2012-2018. Value Health. 2020; 23(Supplement 1):S178. (Poster presentation at the 2020 ISPOR [conference was canceled due to COVID-19]).

44. Chinthammit C(g), Axon DR(g), Bhattacharjee S, Slack M, **Lo-Ciganic W**, Bentley JP, Warholak TL. Health plan performance on high-risk medication use among Medicare Part D beneficiaries: impact of risk adjustment. Value Health. 2020; 23(Supplement 1):S304. (Poster presentation at the 2020 ISPOR [conference was canceled due to COVID-19]).

45. Chinthammit C(g), Bhattacharjee S, Slack M, **Lo-Ciganic W**, Bentley JP, Axon DR(g), Warholak TL. Association of low-income subsidy/dual eligibility and disability with high-risk medication use among Part D Medicare beneficiaries. Value Health. 2020; 23(Supplement 1):S303. (Poster presentation at the 2020 ISPOR [conference was canceled due to COVID-19]).

46. **Lo-Ciganic W**, Donohue JM, Hulsey EG, Barnes S, Li Y, Kuza CC, Yang Q, Buchanich J, Huang JL, Gellad WF. Integrating county-level health, human services, and criminal justice data to predict risk of opioid overdose among Medicaid beneficiaries: a machine learning approach. Value Health. 2020; 23(Supplement 1):S206. (Poster presentation at the 2020 ISPOR [conference was canceled due to COVID-19]).

47. Chang C-Y(g), Hincapie-Castillo JM, Wilson DL, **Lo-Ciganic W**. Evaluation of concurrent use of opioids with high-risk medications among Arizona Medicaid beneficiaries: cross-sectional analysis from 2011 to 2017. Pharmacoepidemiol Drug Saf. 2020; 29(Supplement 3):643. (Poster presentation at the 2020 mid-year ICPE [canceled due to COVID-19]).

48. Bhattacharjee S, Knapp S, Malone DC, Lee JK, Patanwala A, Vadiei N, **Lo-Ciganic W**, Burke WJ. Healthcare expenditures associated with adherence to antidepressant medication management measures during acute and continuation phases of depression treatment among older adults with dementia and major depressive disorders. Value Health. 2019; 22(Supplement 3):S740. (Poster presentation 2019 ISPOR Europe, Copenhagen, Denmark, November 2019).

49. **Lo-Ciganic W**, Huang JL, Zhang H, Weiss J, Donohue J, Gordon A, Gerald C, Malone D, Kwoh CK, Kuza C, Gellad W. Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries. Subst Abus. 2019; 40(4). (Podium presentation at the 2019 Addiction Health Services Research (AHSR), Salt Lake City, UT, USA, October 2019).

50. Goodin AJ, Huang JL, Park H, Hincapie-Castillo JM, Brown JD, Costales B(g), **Lo-Ciganic W**. Trends in controlled substance utilization in Arizona from 2011-2016, by Prescription Class. Subst Abus. 2019; 40(4). (Poster presentation at the 2019 Addiction Health Services Research (AHSR), Salt Lake City, UT, USA, October 2019).

51. Goodin AJ, Huang JL, Park H, Hincapie-Castillo JM, Brown JD, Costales B(g), **Lo-Ciganic W**. Change in buprenorphine prescriptions for opioid use disorder in Arizona from 2011-2016.

Subst Abus. 2019; 40(4). (Podium presentation at the 2019 AHSR, Salt Lake City, UT, USA, October 2019).

52.   Park H, Jiang X(g), Song H-J(p), Childs-Kean LM, **Lo-Ciganic W**, Cook RL, Nelson DR. Direct-acting antiviral therapy among individuals with chronic hepatitis C and substance use disorders: a cohort study. Subst Abus. 2019; 40(4). (Poster presentation at the 2019 AHSR, Salt Lake City, UT, USA, October 2019).

53.   Wang T(p), Ge Y, Gellad WF, Huang JL, Reisfield G, Lee JK, Delcher PC, Hincapie-Castillo JM, Kwoh CK, **Lo-Ciganic W**. Dual trajectories of opioid and benzodiazepine use and risk of opioid overdose among US Medicare beneficiaries. Pharmacoepidemiol Drug Saf. 2019; 28(supplement 2):234. (Poster presentation at the 2019 ICPE, Philadelphia, PA, USA, August 2019).

54.   **Lo-Ciganic W**, Huang JL, Zhang HH, Weiss JC, Wu Y, Kwoh CK, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kuza CC, Gellad WF. Using machine learning to predict risk of opioid overdose in Medicare. Pharmacoepidemiol Drug Saf. 2019; 28(supplement 2):230. (Podium presentation at the 2019 ICPE, Philadelphia, PA, USA, August 2019).

55.   Zhou L(g), Bhattacharjee S, Kwoh CK, Tighe PJ, Reisfield GM, Malone DC, Slack M. **Lo-Ciganic W**. Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among United States Medicare beneficiaries. Pharmacoepidemiol Drug Saf. 2019; 28(supplement 2):230-231. (Podium presentation at the 2019 ICPE, Philadelphia, PA, USA, August 2019).

56.   Chang C-Y(g), Wang C-Y(g), Park H, **Lo-Ciganic W**. Use of immune checkpoint inhibitors and risk of immune-related adverse events among patients with advanced melanoma: a systematic review and network meta-analysis. Pharmacoepidemiol Drug Saf. 2019; 28 (supplement 2):472-473. (Poster presentation at the 2019 ICPE, Philadelphia, PA, USA, August 2019).

57.   Zhou L(g), Bhattacharjee S, Kwoh CK, Tighe PJ, Reisfield GM, Malone DC, Slack M. **Lo-Ciganic W**. Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among United States Medicare beneficiaries. Value Health. 2019; 22(supplement 2): S182. (Podium presentation & Student Spotlight at the 2019 ISPOR 24th Annual International Meeting, New Orleans, LA, USA, May 2019).
   - Student Spotlight (only 8 students were selected)

58.   Zhou L(g), Bhattacharjee S, Kwoh CK, Malone DC, Tighe PJ, Reisfield GM, Slack M. **Lo-Ciganic W**. Association between dual-trajectories of opioid and gabapentinoid use and healthcare expenditures among United States Medicare beneficiaries. Value Health. 2019; 22(supplement 2):S172-S173. (Poster presentation at the 2019 ISPOR 24th Annual International Meeting, New Orleans, LA, USA, May 2019).

59.   Zhou L(g), Bhattacharjee S, Kwoh CK, Tighe PJ, Malone DC, Slack M. **Lo-Ciganic W**. Trends, patient and prescriber characteristics and off-label use of gabapentinoids among United States ambulatory care visits from 2003-2015. Value Health. 2019; 22(supplement 2): S175. (Poster presentation at the 2019 ISPOR 24th Annual International Meeting, New Orleans, LA, USA, May 2019).

60.   Bhattacharjee S, Malone DC, Lee JK, Knapp S, **Lo-Ciganic W**, Burke WJ. Extent and factors associated with adherence to appropriate antidepressant treatment during acute and continuation phase depression treatment among older adults with dementia and major depressive disorder. Value Health. 2019; 22(supplement 2): S287. (Poster presentation at the 2019 ISPOR 24th Annual International Meeting, New Orleans, LA, USA, May 2019).

61.   Bhattacharjee S, Malone DC, Lee JK, Knapp S, **Lo-Ciganic W**, Burke WJ. Health outcomes associated with adherence to Healthcare Effectiveness Data and Information Set (HEDIS) antidepressant medication management measures during acute and continuation phases of depression treatment among older adults with dementia and major depressive disorder. Value Health. 2019; 22(supplement 2): S270. (Poster presentation at the 2019 ISPOR 24th Annual International Meeting, New Orleans, LA, USA, May 2019).

62.   Chang C-Y(g), Park H, **Lo-Ciganic W**. The prevalence of sun protective behaviors across different age groups in the US population: findings from the 2015 Health Interview Survey. Value Health. 2019; 22 (supplement 2): S89. (Poster presentation at the 2019 ISPOR 24th Annual International Meeting, New Orleans, LA, USA, May 2019).

63.   Chang C-Y(g), Park H, **Lo-Ciganic W**. Use of immune checkpoint inhibitors and risk of immune-related adverse events among patients with advanced melanoma: a systematic review and network meta-analysis. Value Health. 2019; 22 (supplement 2): S89. (Poster presentation at the 2019 ISPOR 24th Annual International Meeting, New Orleans, LA, USA, May 2019).

64.   Kumar N(p), **Lo-Ciganic W**, Zhou L(g), Ashbeck E, Kwoh CK. Lipid screening in Medicare beneficiaries with rheumatoid arthritis. Arthritis Rheumatol. 2018; 70(supplement 9):1861. (Poster presentation at the 2018 American College of Rheumatology (ACR) Annual Conference, Chicago, IL, USA, October 2018).

65.   Kollampare S(f), Kwoh CK, **Lo-Ciganic W**, Zhou L(g), Ashbeck E, Sudano D. Serologic screening for coccidioidomycosis among Medicare beneficiaries with rheumatic diseases on biologic response modifiers, corticosteroids, and disease modifying anti-rheumatic drugs (DMARDs). Arthritis Rheumatol. 2018; 70(supplement 9):1221. (Poster presentation at the 2018 ACR Annual Conference, Chicago, IL, USA, October 2018).

66.   Chinthammit C(g), Bhattacharjee S, Slack M, Bentley JP, Warholak TL, **Lo-Ciganic W**. Geographic variation of high-risk medication use among Medicare beneficiaries in the United States. Value Health. 2018; 21(supplement 2): S45-S46. (Poster presentation at the 2018 ISPOR Asia Pacific, Tokyo, Japan, September 2018).

67.   **Lo-Ciganic W**, Gellad WF, Zhou L(g), Donohue JM, Roubal A, Hines L, Lindemann J, Malone DC, Bhattacharjee S, Lee JK, Kwoh CK. Geographic variation of high-risk opioid use and risk of overdose among disabled Medicare beneficiaries in the US from 2011 to 2015. Pharmacoepidemiol Drug Saf. 2018; 27(supplement 2):374. (Podium presentation at the 2018 ICPE, Prague, Czech Republic, August 2018).

68.   Chang C-Y(g), Tan T-W, **Lo-Ciganic W**. Racial and ethnic disparities in lower extremity amputation among Medicare beneficiaries with diabetic foot ulceration and infection in the United States. Pharmacoepidemiol Drug Saf. 2018; 27(supplement 2):70. (Poster presentation at the 2018 ICPE, Prague, Czech Republic, August 2018).

69.   **Lo-Ciganic W**, Gellad WF, Zhou L(g), Donohue JM, Roubal A, Hines L, Lindemann J, Malone DC, Bhattacharjee S, Lee JK, Kwoh CK. Geographic variation of high-risk opioid use and risk of overdose among disabled Medicare beneficiaries in the US from 2011 to 2015. Value Health. 2018; 21(supplement 1). (Podium presentation at the 2018 ISPOR Conference, Baltimore, MD, USA, May 2018).

70.   Bhattacharjee S, Patanwala A, Malone DC, Lee JK, Knapp S, **Lo-Ciganic W**, Warholak T, Burke WJ. Comparison of all-cause mortality and all-cause hospitalization risk for medications

to treat Alzheimer's disease. Value Health. 2018; 21(supplement 1):S204. (Poster presentation at the 2018 ISPOR 23rd Annual International Meeting, Baltimore, MD, USA, May 2018).

71.　Bhattacharjee S, Malone DC, Lee JK, Knapp S, **Lo-Ciganic W**, Burke WJ. Extent and predictors of potentially inappropriate antidepressant use among older adults with dementia and major depressive disorder. Value Health. 2018; 21(supplement 1):S189. (Poster presentation at the 2018 ISPOR 23rd Annual International Meeting, Baltimore, MD, USA, May 2018).
- Awarded as Finalist for Research Poster presentation award, indicating top 10% of accepted abstracts.

72.　**Lo-Ciganic W**, Gellad WF, Zhou L(g), Donohue JM, Roubal A, Hines L, Lindemann J, Malone DC, Bhattacharjee S, Lee JK, Kwoh CK. Geographic variation of high-risk opioid use and risk of overdose among disabled Medicare beneficiaries in the US from 2011-2015. Value Health. 2018; 21(supplement 1):S2. (Podium presentation at the 2018 ISPOR 23rd Annual International Meeting, Baltimore, MD, USA, May 2018).

73.　Zhou L(g), Kwoh CK, Ran D, Ashbeck EL, **Lo-Ciganic W.** Lack of association between beta blocker use and reduction in joint pain and analgesic use among participants with symptomatic radiographic knee osteoarthritis. Value Health. 2018; 21(supplement 1):S200. (Poster presentation at the 2018 ISPOR 23rd Annual International Meeting, Baltimore, MD, USA, May 2018).

74.　Zhou L(g), Kwoh CK, **Lo-Ciganic W**. Trends in baseline retinal examinations and associated factors among new initiators of hydroxychloroquine in Medicare: 2011-2015. Value Health. 2018; 21(supplement 1):S118-S119. (Poster presentation at the 2018 ISPOR 23rd Annual International Meeting, Baltimore, MD, USA, May 2018).

75.　Kennedy J, Seymour CW, Chang C-C, Giarard TD, Kim C, **Lo-Ciganic J**, Marroquin OC, Angus DC, Donohue JM. Patterns of inpatient, intensive care, and post-discharge opioid prescribing to opioid-naïve patients in a large health system. Am J Respir Crit Care Med. 2018;197:A7667. (Poster presentation at the American Thoracic Society 2018 International Conference, San Diego, CA, USA, May 2018).

76.　Chien H-C(p), **Lo-Ciganic W**, Kwoh CK, Kao-Yang Y-H. Use of aromatase inhibitors and risk of arthralgia among Taiwanese breast cancer women: a nation-wide claims analysis. Arthritis Rheumatol. 2017; 69(supplement 10):1866. (Podium presentation at the 2017 ACR Annual Conference, San Diego, CA, USA, November 2017).

77.　Sudano DG, Kowh CK, Zhou L(g), Ashbeck EL, **Lo-Ciganic W**. Use of disease-modifying anti-rheumatic drugs, biologic response modifiers and corticosteroids, and subsequent risk of coccidioidomycosis infection among Medicare beneficiaries. Arthritis Rheumatol. 2017; 69(supplement 10):2906. (Podium presentation at the 2017 ACR Annual Conference, San Diego, CA, USA, November 2017).

78.　Bhattacharjee S, Malone DC, Warholak T, Knapp S, **Lo-Ciganic W**, Lee JK, Burke WJ. Comparison of fall and fracture risk for medications to treat Alzheimer's disease. J Manag Care Pharm. 2017 (Poster presentation at the 2017 American Managed Care Pharmacy (AMCP) Nexus Annual meeting, Dallas, TX, USA, October 2017)

79.　**Lo-Ciganic W**, Gellad WF, Donohue JM, Zhou L(g), Roubal A, Hines L, Lindemann J, Lee JK, Malone DC, Bhattacharjee S, Kwoh CK. Geographic variation of potentially inappropriate prescription opioid use among disabled Medicare beneficiaries. Pharmacoepidemiol Drug Saf. 2017; 26: 627. (Poster presentation at the 2017 ICPE, Montreal, Canada, August 2017).

80.   **Lo-Ciganic W**, Donohue JM, Kim JY, Krans EE, Kelley D, James E, Jarlenski M. Trajectories of buprenorphine opioid agonist therapy during pregnancy in a large Medicaid program. Pharmacoepidemiol Drug Saf. 2017; 26(supplement 2):13-14. (Podium presentation at the 2017 ICPE, Montreal, Canada, August 2017).

81.   **Lo-Ciganic W**, Donohue JM, Malone DC, Gellad WF. Characteristics of new hepatitis C virus therapy utilization in a large Medicaid program. Am J Pharm Educ. 2017. (Poster presentation. Presented as New Investigator Award Winner poster presentation at the American Association of College of Pharmacy Annual Meeting, Nashville, TN, USA, July 2017).
   - New Investigator Award Winner poster presentation at the American Association of College of Pharmacy.

82.   Zhou L(g), Kwoh CK, Gellad WF, Donohue JM, Roubal A, Hines L, Malone DC, Bhattacharjee S, Lee JK, Lindemann J, Bell M, Westra J(g), **Lo-Ciganic W**. Geographic variation of inappropriate prescription opioid use among disabled Medicare beneficiaries. Value Health. 2017; 20(5):A7. (Podium presentation at the 2017 ISPOR 22nd Annual International Meeting, Boston, MA, USA, May 2017).
   - Awarded as the Best Student Podium Presentation.

83.   Hsieh P(r), Chou C, Hsu W, **Lo-Ciganic W**. Using machine learning to predict the technical difficulty of colorectal endoscopic submucosal dissection in endoscopists with limited experience. J Gastroenterol Hepatol 2016; 31(supplement 3):269 (Podium presentation at the 58th Annual Meeting of the Japanese Society of Gastroenterology, Kansai, Japan, November 2016).

84.   **Lo-Ciganic W**, Floden L, Ashbeck EL, Zhou L(g), Kwoh CK. Analgesic use and subsequent risk of falls in participants with or at risk of knee osteoarthritis. Arthritis Rheumatol. 2016; 68(supplement 10). (Poster presentation at the 2016 American College of Rheumatology (ACR) Annual Conference, Washington, D.C., USA, November 2016).

85.   **Lo-Ciganic W,** Donohue JM, Jones BL, Perera S, Thorpe JM, Thorpe CT, Marcum ZA, Gellad WF. Association between trajectories of diabetes medication adherence and hospitalization risk in a large Medicaid program. Pharmacoepidemiol Drug Saf. 2016; 25(supplement 3):52. (Poster presentation at the 2016 ICPE, Dublin, Ireland, Aug 2016).

86.   **Lo-Ciganic W**, Gellad WF, Huskamp HA, Choudhry NK, Zhang R, Chang CH, Jones BL, Richards-Shubik S, Guclu H, Donohue JM. Who were the early adopters of dabigatran: an application of group-based trajectory models. Value Health. 2016; 19(3):A58. (Poster presentation at 2016 ISPOR 21st Annual Meeting, Washington, D.C., USA, May 2016).

87.   Almutairi A(g), Zhou L(g), Lee JK, Slack M, Martin JR, **Lo-Ciganic W**. Comparative effectiveness and safety of novel oral anticoagulants (NOACs) versus vitamin K antagnoists (VKA) in atrial fibrillation: a meta-analysis of observational studies. Value Health. 2016; 19(3):A41. (Poster presentation at the 2016 ISPOR 21th Annual Meeting, Washington, D.C., USA, May 2016).

88.   Anderson TS, **Lo-Ciganic W,** Gellad WF, Zhang R, Huskamp HA, Choudhry NK, Chang C-H, Richards-Shubik S, Guclu H, Donohue JM. Physician adoption of new cardiovascular drugs: does novelty matter? J Gen Intern Med. 2016; 31(supplement 2):S339. (Poster presentation at the 2016 Society of General Internal Medicine Annual Meeting, Hollywood, FL, USA, May 2016).

89.   **Lo-Ciganic W,** Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Donohue JM. Trajectories of buprenorphine treatment and associated emergency department and inpatient use in a large

Medicaid Program. Value Health. 2015; 18(3):A129. (Poster presentation at the 2015 ISPOR 20th Annual Meeting, Philadelphia, PA, USA, May 2015).

- Awarded as ISPOR Finalist for Research Poster presentation award, indicating top 10% of accepted abstracts.

90. **Lo-Ciganic W,** Donohue JM, Thorpe JM, Perera S, Thorpe CT, Marcum ZA, Gellad WF. Using machine learning to examine medication adherence thresholds and risk of hospitalization. Pharmacoepidemol Drug Saf. 2015; 24:210-211. (Podium presentation at the 2015 ICPE, Boston, MA, USA, August 2015).

91. **Lo-Ciganic W,** Gellad WF, Gordon AJ, Cochran G, Donohue JM. Trajectories of buprenorphine treatment and associated emergency department and inpatient use in a large Medicaid program. Pharmacoepidemiol Drug Safety. 2015; 24:27-28. (Podium presentation at the 2015 ICPE, Boston, MA, USA, August 2015).

92. **Lo-Ciganic W,** Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Donohue JM. Associations between buprenorphine treatment trajectories and clinical outcomes in a large Medicaid program. Drug Alcohol Depend. 2015; 156:e132. (Poster presentation at the 2015 College on Problems of Drug Dependence (CPDD) annual meeting, Phoenix, AZ, USA, June 2015).

93. **Lo-Ciganic W,** Donohue JM, Thorpe JM, Perera S, Thorpe CT, Marcum ZA, Gellad WF. Examining a threshold of adherence to oral hypoglycemic agents relevant to clinical outcomes in diabetes: a tree-structured survival model. Value Health. 2014; 17(3):A253. (Poster presentation at the 2014 ISPOR 19th Annual Meeting, Montreal, ON, Canada, May - June 2014).

94. Gordon AJ, **Lo-Ciganic W**, Cochran G, Gellad WF, Donohue JM. Characteristics of buprenorphine opioid agonist treatment in a longitudinal US Medicaid population. Drug Alcohol Depend. 2015; 146:e126. DOI:10.1016/j.drugalcdep.2014.09.260. (Poster presentation at the 2014 College on Problems of Drug Dependence (CPDD) annual meeting, San Juan, Puerto Rico, June 2014).

95. Zgibor JC, Tu LC, Kuo SC, Saul M, Solano FX, **Lo-Ciganic WH,** Ruppert K. The impact of timing of insulin on the incidence of macrovascular complications. Diabetes. 2014; 63(supplement 1):A400. (Poster presentation at the 74th Scientific Sessions of the American Diabetes Association, San Francisco, CA, USA, June 2014).

96. Zgibor JC, Tu LC, Kuo SC, **Lo-Ciganic WH,** Solano FX, Ruppert K. Timing of insulin initiation and diabetes complications in a large health system: developing a profile for secondary prevention. Diabetes. 2013; 62(supplement 1):A315. (Podium presentation at the 73th Scientific Sessions of the American Diabetes Association, Chicago, IL, USA, June 2013).

97. Schlenk EA, Vander Bilt J, **Lo-Ciganic W**, Woody SE, Zgibor JC, Conroy MB, Kwoh CK, Newman AB. Integration of a healthy aging program Into the Arthritis Foundation Exercise Program: six-month results. Arthritis Rheum. 2012; 64(10): S1024-S1025. (Podium presentation at the 2012 ACR annual conference, Washington, D.C., USA, Nov 2012).

98. **Lo-Ciganic W**, Boudreau R, Zgibor JC, Donohue JM, Gray S, Newman AB, Simonsick EM, Hanlon JT. Time-trend utilization of statins in community-dwelling older adults. Gerontologist. 2012; 52(supplement 1):214. (Poster presentation at the Annual Scientific Meeting of the Gerontological Society of America, November 2012).

99. Kramer MK, Mcwilliams J, **Lo-Ciganic W**, Siminerio L. Evaluation of the group lifestyle balance program delivered by diabetes educators in the US: one-year follow up. Diabetes. 2011;

60(supplement 1):A201. (Poster presentation at the 71th Scientific Sessions of the American Diabetes Association, San Diego, CA, USA, June 2011).

100. **Lo-Ciganic W**, Wolf D, Zgibor JC. Implementing the chronic care model in primary care: influence of clinical outcomes of care. Diabetes. 2011; 60(supplement 1):A196. (Poster presentation spotlight at the 71th Scientific Sessions of the American Diabetes Association, San Diego, CA, USA, June 2011).

Media coverage
1.   UF Health researchers creating A.I. tool to identify patients with high-risk of opioid abuse has highlighted in the WCJB TV20 on August 13, 2021. https://www.wcjb.com/2021/08/13/uf-health-researchers-creating-ai-tool-identify-patients-with-high-risk-opioid-abuse/

2.   2017 PhRMA Foundation Research Starter Award had been reported in over 40 local and national news, radio stations and TV news such as US News and Washington Times. For example, interviewed by the KGUN-9 TV News: https://www.youtube.com/watch?v=DPoEetdbxpc

3.   Medication adherence and risk of hospitalization: can machine learning help establish thresholds? The innovation and relevance of the work, "Using machine learning to examine medication adherence thresholds and risk of hospitalization" has been highlighted in the *Medical Care blog on August 21, 2015.* http://journals.lww.com/lww-medicalcare/blog/PointCounterpoint/pages/post.aspx?PostID=37

PROFESSIONAL ACTIVITIES: TEACHING

Courses Taught

Years	Institution, Program	Course #, title	Credits/hours	Role
2023 fall	University of Florida, College of Pharmacy, Graduate Program	PHA 6935: Introduction to Artificial Intelligence in Pharmacy	3 credits hours, (50% effort)	Primary coordiner/instructor
2019-2023 spring	University of Florida, College of Pharmacy, Pharm D Program	PHA5244: Principles of Evidence-Based Practice (Co-coordinator)	3 credits hours, 200 to 250 students (50%-67% effort)	Primary coordinator/instructor
2022-2023 spring	University of Florida, College of Pharmacy, Pharm D Program	PHA 5242: Principles of Pharmacy Informatics	2 credits hours, 18-20	Lecturer (1 lecture)
2020-2021 fall	University of Florida, College of Pharmacy, Department of Pharmaceutical Outcomes and Policy Graduate Program	PHA 6268 Pharmacoepidemiology and Drug Safety	3 credits hours, 5-20 students	Primary coordinator/instructor
2018-2023 spring	University of Florida, College of Pharmacy, Department of Pharmaceutical	PHA6265: Introduction to	3 credits hours, 5-10 students	Lecturer (2 lectures)

	Outcomes and Policy Graduate Program	Pharmaceutical Outcomes & Policy		
2018 spring	University of Arizona, College of Pharmacy, Health Pharmaceutical Outcome Graduate Program	SAS workshop	3 credit hours, 4 students (100% effort)	Primary coordinator/ instructor
2016-2018 spring	University of Arizona, College of Pharmacy, PharmD Program	PhPr 861A: Drug Literature Evaluation and Statistical Methods	2 credit hours, 100-140 students (97.5% effort)	Primary coordinator/ instructor
2016 spring	University of Arizona, College of Pharmacy, Health Pharmaceutical Outcome Graduate Program	PhSc 596E: Graduate Seminar	1 credit hour, 15 students (95% effort)	Primary coordinator/ instructor
2016 fall	University of Arizona, College of Pharmacy, Health Pharmaceutical Outcome Graduate Program	PhSc 513C: Health Technology Assessment	3 credit hours, 8 students (60% effort)	Primary coordinator/ instructor
2010, 2011	University of Pittsburgh, Institute for Clinical Research and Education	CLRES 2005: Clinical Research Methods	7 hours per week for 2.5 months; 35-75 students	Primary teaching assistant (recitation session)

Invited lectures, seminars, tutorials, workshop & continuing education courses

Year	Institution, Program	Course #, title	Lecture title (role)
03/2022	2023 American Pharmacy Association Annual Meeting & Exposition	The Future is Now	AI and Machine Learning in Medicine (Key speaker)
11/2022	The 4th Taiwan Joint Conference of Pharmacy and Pharmaceutical Sciences	AI & Telehealth in Pharmacy Practices	Telehealth Pharmacy Education & Practice in US (Session speaker)
09/2022	National Institute on Drug Abuse, Clinical Trial Network	Target Trial Emulation in Observational Research and Translational Testing of Advanced Digital Health Tools for SUD Prevention and Treatment	Development and Implementation of a machine-learning based opioid overdose risk prediction tool in the electronic health records (Workshop panelist)
08/2022	University of Florida, College of Pharmacy	PHA5233 Pharmacoepidemiology and drug safety	Artificial Intelligence and machine learning in

			pharmacy practice (Lecturer)
05/2022	University of Florida, Clinical and Translational Science Institute (CTSI)	Precision Health Forum Series	Using Machine Learning Approaches to Predict Opioid Overdose and Opioid Use Disorder: the Current State and Challenges
02/2022	American College of Clinical Pharmacy (AACP)	Training lecture	Can machine learning improve pharmaceutical outcomes & patient care?
12/2021	University of Pittsburgh Alumni Association	Health academy series	Harnessing big data to save lives: How machine learning tools can help predict opioid overdose (Key speaker)
12/2021	University of Florida, College of Pharmacy	PHA5930 Seminar in Pharmacy Research	Application of advanced predictive analytics in pharmaceutical outcomes research (Lecturer)
11/2021	The 3rd Taiwan Joint Conference of Pharmacy and Pharmaceutical Sciences	Advancing with AI technology through the pandemic series	Application of machine learning in pharmaceutical outcomes research: the current state and challenges (Session speaker)
04/2021	University of North Carolina at Chapel Hills, Department of Pharmaceutical Outcomes and Policy (DPOP)	University of North Carolina at Chapel Hills, DPOP Seminar	Using Machine Learning Approaches to Predict Opioid Overdose and Opioid Use Disorder (OUD) (Speaker)
01/2021	Brandeis-Harvard NIDA Center	Brandeis-Harvard Methods Workshop (4 hours)	Applying Group-Based Trajectory Modeling in Health Outcomes Research (Lecturer)
09/2020	University of Utah, College of Medicine, Department of Internal Medicine, Division of Epidemiology	Special invited seminar	IDEAS Seminar Presentation Applying Advanced Predictive Analytics in Pharmaceutical Outcomes Research (Speaker)
09/2020	University of Utah, College of Medicine, Department of Internal Medicine, Division of Epidemiology	Special invited seminar	GIN on the Rocks Presentation (GOTR): Using machine learning to predict opioid overdose and

			opioid use disorder (Speaker)
09/2020	Dept. of Pharmaceutical Science & Technology, Maulana Abul Kalam Azad University of Technology (India)	Special invited seminar	Applying Analytics in Pharmaceutical Outcomes Research (Speaker)
07/2020, 07/2021	ISPOR annual conference offered virtually (due to COVID-19)	Annual conference short course (4 hours)	Introduction to machine learning methods (Main coordinator and lecturer)
02/2019	Gainesville Geriatric Research Education and Clinical Centers (GRECC)	Monthly investigator luncheon	Applying advanced analytics in pharmaceutical outcomes research (Spearker)
2019, spring	University of Florida, College of Pharmacy, Department of Pharmaceutical Outcomes & Policy	PHA 6265: Introduction to Pharmaceutical Outcomes & Policy (2 ×1.5 hours, 8 students)	Developing a research question; Predictive modeling (Lecturer)
06/2018	National Cheng-Kung University, College of Pharmacy, Tainan, Taiwan	Special invited seminar speaker	Applying advanced analytics in pharmaceutical outcomes research
11/2016	University of Arizona, College of Public Health	CPH 587: Analysis Methods for Health Policy Decision Makers (1 hour, 12 students)	Introduction to machine learning methods (Speaker)
10/2016	University of Arizona Arthritis Center	Annual Arthritis Conversations and Luncheon	Researcher speaker and panel discussant
09/2016	University of Arizona, College of Medicine, Division of Rheumatology	Rheumatology Grand Round	Analgesic pain management and adverse drug reactions with opioid use in older adults (Speaker)
09/2015	The University of Arizona, College of Pharmacy	Workshop: Training Program in Health Outcomes and Pharmacoeconomic Research (1 hour, 60 attendees)	Data sources for pharmacoeconomic and health service research (Lecturer)
09/2015	University of Arizona, College of Public Health	Graduate Seminar	Applications of pharmacoepidemiological methods to evaluate medication utilization and to

			improve pharmaceutical outcomes (Speaker)
02/2015	University of Arizona Arthritis Center, Tucson	Annual Arthritis Conversations and Luncheon	Round table researcher host
03/2014	University of Pittsburgh, School of Medicine/Graduate School of Public Health	EPIDEM 2850: Introduction to Pharmacoepidemiology, Division of Geriatric Medicine	Changes in cholesterol-lowering medications use over a decade, and statins and gait speed decline in community dwelling older adults (Lecturer)
03/2011	University of Pittsburgh, School of Medicine/Graduate School of Public Health	EPIDEM 2850: Introduction to Pharmacoepidemiology, Division of Geriatric Medicine	Aspirin, nonaspirin nonsteroidal anti-inflammatory, acetaminophen and risk of ovarian cancer (Lecturer)
2011	University of Pittsburgh, Graduate School of Public Health	EPIDEM 2183: Reading, Analyzing and Interpreting the Public Health and Medical Literature	Causality (Lecturer)

Major Advisor & Committee Chair for Graduate Student Theses, and Dissertations

Years served	Name of Student	Program/Degree Award	Title of Thesis/Dissertation or current status (expected graduation year)
2022-present	Hsin-Ming Grace Wang	PhD, Pharmaceutical Outcomes & Policy, University of Florida (UF POP)	2nd year PhD student (Fall 2024) Title: "Antidepressant and benzodiazepine use and associated risk of falls and related injuries in older adults with depression"
2020-present	Shu Huang	PhD, UF POP	3rd year PhD student (fall 2023) Title: "Risk prediction of suicide-related outcomes in patients with prescription opioid use"
2021-present	Motomori Lewis	PhD, UF POP	5th year PhD student (fall 2023) Title: "Geographic variation patterns in safety of prescription opioid quality measures and buprenorphine continuity for opioid use disorder among Medicare beneficiaries"
2019-present	Seongkyeong Yang	PhD, UF POP	4th year PhD student (fall 2023)/ Title: "Real-world migraine treatment patterns and associated cardiovascular

			disease risk in Medicare beneficiaries with migraine"
2018-2022	Ching-Yuan (Peggy) Chang	PhD, UF POP	Final dissertation defense: March 20, 2022 Title: "Endocrine Therapy, Prescription Opioid, and Antidepressant Use among Breast Cancer Survivors in the US"
2016-2019	Lili Zhou	PhD, Health Pharmaceutical Outcomes, University of Arizona (UA)	Final dissertation defense date: April 26, 2019 Title: 'Trends and Trajectories of Gabapentinoid Use and Its Associations with Subsequent Health Outcomes and Healthcare Expenditures in the United States'

Service on Masters or Doctoral Committees

Years served	Name of Student	Degree Award (year of graduation)	Title of Thesis/Dissertation
2022-present	Ikenna Unigwe	PhD, UF POP (TBD)	Adherence trajectories of PrEP and HIV incidence, using group- based trajectory modeling (Major advisor: Haesuk Park)
2022-present	Shailina Keshwani	PhD, UF POP (TBD)	TBD (Major advisor: Steve Smith)
2021-2023	Earl Morris	PhD, UF POP (2023)	Treatment patterns and cardiorenal outcomes associated with xanthine oxidase inhibitor use in older adults (Major advisors: Scott Vouri / Steve Smith)
2021-2023	Cassidi McDaniel	PhD, Health Outcomes Research and Policy, Auburn University (2023)	Unpacking the complexity of diabetes care through investigating disease control and therapeutic inertia among patients with type 2 diabetes (Major advisor: Chiahung Chou)
2020-2022	Shailina Keshwani	MS, UF POP (2021)	Trends in Buprenorphine Use for Opioid Use Disorder Following Prior Authorization Policies in Medicaid from 2012 to 2020 (Major advisor: Juan Hincapie-Castillo)
2018-present	Cheng (Alice) Chen	PhD, UF POP (2021)	Utilization, safety, and effectiveness of prescription gabapentinoids and opioids among older adults (Major advisor: Yu-Jung Wei)

2019-2020	Xinyi Wang	PhD, UF POP (2020)	The cascade of hepatitis C virus care in individuals with substance use disorders (major advisor: Haesuk Park)
2017-2018	Chanadda Chinthammit	PhD, University of Arizona (2018)	Use of high-risk medications among Medicare Part D beneficiaries (major advisor: Terri Warholak)
2015	Diana Sun	PhD, University of Arizona (2015)	Characterizing response patterns to ranibizumab therapy in patients with wet age-related macular degeneration: a latent class growth analysis

Advisor for Professional or Graduate Student Independent Study, Internship, Post-doctoral Fellows or Residents Projects

Years	Name of Student	Program	Project title
2020-2021	Macy Boren & Abigale Lipe	PharmD	Trends in the Management of Headache Disorders in US Emergency Departments: Analysis of 2007-2018 National Hospital Ambulatory Medical Care Survey Data
2020-2022	Shu Huang	PhD	A systematic review of risk factors and predictive modeling for suicide-related outcomes among patients with pain conditions
2019-2020	Morgan Carson	PharmD	Deprescribing approaches for opioid and/or benzodiazepine use: a narrative review
2017	Hsu-Chih Chien	Postdoctoral fellow	Use of aromatase inhibitors and risk of arthritis and musculoskeletal problems
2017	Lili Zhou	PhD	Use of disease-modifying antirheumatic drugs, biologic response modifiers and corticosteroids, and subsequent risk of coccidioidomycosis infection among Medicare beneficiaries
2017	Jiaheng Xie	PhD in Management Information System	Improving readmission prediction with social media: a trajectory-aware deep learning approach
2016-2018	Lili Zhou	PhD	Geographic variation of problematic opioid use in Medicare
2016-2017	Jordan Westra	MPH (internship)	Geographic variation in analgesic Use among Medicare Beneficiaries with chronic lower extremity osteoarthritis or lower back pain

2016	Chanadda Chinthammit	PhD	Trajectories of gait speed decline and patterns of analgesic use in patients with- or at-risk of knee osteoarthritis: data from the Osteoarthritis Initiative
2015-2016	Abdulaali Almutairi	PhD	Effectiveness and safety of non-vitamin K oral anticoagulants for non-valvular atrial fibrillation or venous thromboembolism: systematic review and meta-analyses.
2015-2016	Erik Overgard	PharmD	Senior project: Assessing the impact of education about Medication Assisted Therapy has on probation and parole officers

Primary Mentor, Co-Mentor or Consultant for Faculty

Years	Name of Faculty	Role	Institution
2023-present	Rachel Reise	Co-Mentor	Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida (UF)
2022-present	Md Mahmudul Hasan	Primary Mentor	Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida (UF)
2022-present	Sarah Kim	Co-Mentor	Department of Pharmaceutics, College of Pharmacy, UF
2022-present	Jennifer Miles	Consult (K99/R00)	Institute of Health, Health Care Policy and Aging Research, Rutgers University
2022-present	Ruiyun (Frances) Chen	Primary Mentor	Department of Criminal Justice and Criminology, Georgia State University Funded through NIH's Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity (AIM-AHEAD) Fellowship Program

PROFESSIONAL ACTIVITIES: GRANTS & CONTRACTS

Previous Grant/Contract Support

Grant Period	Grant Number and Title	Role, effort	Source	Amount
05/2020-06/2023	Trajectories of apixaban for extended treatment of recurrent venous thromboembolism: a	Co-I, 8%	Bristol Myers Squibb	$795,945 (total, over 2 years)

	retrospective cohort study (PI: Park)			
05/2021-03/2023	Evaluation of utilization patterns of cough medications in the United States (MPI: Lo-Ciganic & Hincapie-Castillo)	MPI, 7.5%	Merck Inc.	$275,829 (total)
03/2021-09/2022	1 I01HX002191-01A2 Nursing unit design and hospital falls (PI: Shorr)	Co-I, 20%	Veterans Affairs (VA) Merit	$36,266 (total; no indirect)
09/2017-06/2022 (R01)	R01DA044985, Using machine Learning to Predict Problematic Opioid Use (PI: Gellad)	Consortium-PI, 30%	National Institute of Drug Abuse (NIDA) / University of Pittsburgh	$739,051 (total, subcontract)
05/2019-01/2022 (R21)	R21AG060308, Developing a Real-Time Trajectory Tool to Identify Potentially Unsafe Concurrent Opioid and Benzodiazepine Use among Older Adults (PI: Lo-Ciganic)	PI, 20%	National Institute on Aging (NIA)	$446,997 (total, over 2 years)
08/2020-01/2022 (R21)	R21AG060308, Developing a Real-Time Trajectory Tool to Identify Potentially Unsafe Concurrent Opioid and Benzodiazepine Use among Older Adults (PI: Lo-Ciganic)	PI, 0%	NIA (Administrative Supplement)	$76,250 (total)
01/2020-02/2021	Leveraging social media data for evaluation of drug use trends after opioid policies (PI: Hincapie-Castillo)	Co-Mentor, 0%	American Association of College of Pharmacy (AACP) New Investigator Award	$10,000 (total)
07/2018-06/2020	Machine learning and opioid overdoses in Allegheny County (Multi-PI: Gellad/Donohue/Lo-Ciganic)	MPI, 19%	Richard King Mellon Foundation / University of Pittsburgh	$61,818 (total over 2 years, subcontract)

04/2019-03/2020 (internal grant)	Using machine learning to predict direct-acting antiviral treatment failure in patients with chronic hepatitis C virus infection (PI: Park)	Co-I, 10%	University of Florida, Clinical and Translational Science Institute (CTSI)	$68,000 (direct, over 1 years)
08/2017-06/2019	1R03MH114503-01, Depression Treatment and Outcomes among Older Adults with Dementia in the United States (PI: Bhattacharjee)	Co-Investigator, 1%	National Institute of Mental Health (NIMH)	$100,000 (total direct cost)
07/2017-03/2019	Research Starter Award in Health Outcomes, Using Advanced Analytics to Predict Problematic Prescription Opioid Use in Medicare	PI, 10%	Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation	$100,000 (total direct cost)
07/01/2017-06/30/2018	Pennsylvania Medicaid Research and Data Analysis to Improve Quality of Care for Opioid Use Disorder in Perinatal Period	Consultant, 9%	Pennsylvania Department of Health Services / University of Pittsburgh Pennsylvania Medicaid Research Center (MRC)	$10,000 (subcontract)
2013-2017	NHLBI R01HL 119246, The Role of Physician Networks in the Adoption of New Prescription Drugs (PI: Donohue)	Consultant (2016-2017)	National Heart, Lung and Blood Institute (NHLBI)	$10,000 (total direct cost)
01/2016-03/2017	New Investigator Award, Adherence Trajectories of New Hepatitis C Virus Therapy in a Large Medicaid Program	PI, 10%	American Association of College of Pharmacy (AACP)	$10,873 (total)
09/2015-08/2017	UAHS CDA13, Using machine Learning to Predict Problematic Opioid Use	PI, 75%	University of Arizona Health Sciences Center	$225,050
2011-2013	IST # LANTU R 06017, Early insulin uses and incidence of diabetes	Statistical consultants, 5%	Sanofi Aventis Global	$200,000

complications: prediction
and decision analysis

Current Grants and Contracts Support

Grant Period	Grant Number and Title	Role, effort	Source	Amount
09/2020-05/2025 (R01)	R01MH121907, Linking VA and non-VA data to study the risk of suicide in chronic pain patients (PI: Pathak)	Co-I, 8%-15%	National Institute of Mental Health (NIMH)/Cornell university	$3,505,137 ($497,166 total direct for UF subaward, over 5 years)
07/2020-12/2023	Implementing Opioid Risk Prediction Models (PI: Gellad)	Site PI, 10%	Richard King Mellon Foundation / University of Pittsburgh	$63,494 (total, over 3 years, subcontract)
07/2021-04/2026 (R01)	1R01DA050676 - 01A1 Developing and Evaluating a Machine-Learning Opioid Prediction & Risk-Stratification E-Platform (DEMONSTRATE) (PI: Lo-Ciganic)	PI, 30%	National Institute of Drug Abuse (NIDA)	$3,237,039 (total, over 5 years)
07/2022-04/2027 (R01)	2R01DA044985-04 Machine-Learning Prediction and Reducing Overdoses with EHR Nudges (mPROVEN) (PI: Gellad)	Site PI, 10%-20%	NIDA	~$3,500,000 ($291,083 total direct for UF subaward, over 5 years)
07/2023-06/2024	Cardiovascular Outcomes in Narcolepsy	Co-PI, 14%	Sleep Research Society Foundation	$392,868 (total, no IDC)

Grants and Contracts Pending

Grant Period	Grant Number and Title	Role, effort	Source	Amount
12/2023-11/2028	R01 DA057886-01 Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool	Co-Investigator, 5% to 10%	NIDA	$3,761,575 (total)
02/2023-04/2026	R01 DA058302-01 Benzodiazepine deprescription in people receiving opioid treatment	Co-Investigator, 5% to 15%	NIDA	$2,096,991 (total)
07/2024-07/2025	Developing and Evaluating a Machine-Learning Buprenorphine Care Discontinuity Prediction E-Tool (BUP-CARE)	MPI, 8%	NIDA	$433,666 (total)